(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/29072 A2

(51) International Patent Classification[7]: C12N 15/85

(21) International Application Number: PCT/EP01/11514

(22) International Filing Date: 5 October 2001 (05.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/684,552	6 October 2000 (06.10.2000)	US
60/327,562	6 October 2000 (06.10.2000)	US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH** [AT/AT]; Brunner Strasse 59, 1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIM, Jin, Gwan** [US/US]; 11520 Seneca Forest Circle, Germantown, MD 20876 (US). **SMITH, Theodore** [US/US]; 3346 Knolls Parkway, Ijamsville, MD 21754 (US). **STEVENSON, Susan, C.** [US/US]; 10974 Horseshoe Drive, Frederick, MD 21701 (US). **KALEKO, Michael** [US/US]; 8 Hearthstone Court, Rockville, MD 20854 (US).

(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/29072 A2

(54) Title: TARGETING MOLECULES

(57) Abstract: The present invention relates to targeting molecules which are useful to specifically target an adenoviral particle to a desired cell type. These targeting molecules comprise a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain. Further provided are polynucleotides encoding such targeting molecule, expression vectors including such polynucleotides, and methods to target an adenoviral particle to a cell, as well as methods to deliver a heterologous gene selectively to a cell.

TARGETING MOLECULES

FIELD OF THE INVENTION

The present invention relates generally to the fields of molecular biology and gene theapy. More specifically, the present invention relates to the production of targeting molecules for the purpose of cell-specific targeting of adenoviral particles.

BACKGROUND OF THE INVENTION

Adenoviruses are DNA viruses with genomes that are linear, double-stranded DNA molecules of about 36 kilobase pairs length. Each extremity of the viral genome has a short sequence known as the inverted terminal repeat (ITR), which is necessary for viral replication. The well-characterized molecular genetics of adenovirus render it an advantageous vector for gene transfer. The adenovirus delivers such genes to eukaryotic cells by binding to cellular receptors.

The adenovirus fiber protein is responsible for such attachment. The fiber protein consists of three domains: a tail domain, a rod-like shaft portion, and a globular head portion which contains the receptor binding region. The fiber spike is a homotrimer, and there are 12 spikes per virion. Human adenoviruses may bind to and infect a broad range of cultured cell lines and primary tissues from different species.

Adenovirus tropism is determined by attachment to specific cell surface molecules. Many adenovirus serotypes, except those in subgroup B, bind to a cell surface molecule called coxsackie-adenovirus receptor (CAR). Human CAR is a 365 amino acid transmembrane protein (46kDa) with a short leader, a 222 amino acid extracellular domain, a membrane spanning helical domain, and a 107 amino acid intracellular domain (DNA sequence: Seq. Id. No.1 ; protein sequence: Seq. Id. No.2, see example 14). The extracellular region contains two immunoglobulin (Ig)-related structural domains. CAR is widely expressed in vivo, accounting for the widespread tissue distribution of systemically administered adenoviral vectors. Adenovirus serotype 3 (Ad3), which belongs to subgroup B, has been shown to bind to a different, as yet unidentified, receptor.

The ability of adenoviruses to infect a broad range of cell types, however, is not favorable if the desired target is a specific tissue or cell type. In addition to being inefficient, transduction of non-target cells may have undesirable effects. Successful vector targeting strategies may overcome these problems by directing the entire vector dose to the appropriate site. This may improve the safety profile of the vector and permit the use of lower vector doses, which would be less toxic and less immunogenic. Further, adenoviral vector targeting may permit transduction of cell types that are refractory to adenovirus infection, such as, for example, cells of the hematopoietic system or tumor cells. Thus, the targeting of adenoviral particles could expand the clinical utility of adenoviral vector-mediated gene therapy.

SUMMARY OF THE INVENTION

The present invention provides novel targeting molecules which are useful to specifically target an adenoviral particle to a desired cell type. These targeting molecules comprise a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain. The trimerization domain facilitates the formation of trimeric versions of the targeting molecules, which are capable of forming stable complexes with adenoviral particles and demonstrate an enhanced ability to transduce target cells as compared to monomeric versions.

The targeting molecules of the invention ablate the natural tropism of adenoviral vectors and simultaneously redirect them to the target of choice. Furthermore, the targeting of adenoviral vectors with the described strategy does not require the time-consuming generation of modified adenoviral vectors. In contrast, adenoviral vectors that are employed in combination with the targeting molecules of the invention can be prepared and grown to high titer using normal protocols and standard cell lines. Thus, the described targeting molecules provide an efficient, rapid and facile means for purposes of cell-specific targeting.

Accordingly, the invention provides a method of targeting an adenoviral particle to a cell which expresses a cell surface molecule comprising the steps of contacting said adenoviral particle with the targeting molecule of the present invention to form a complex comprising said adenoviral particle and said targeting molecule and contacting said cell with said complex.

In the context of strategies to accomplish gene therapy, the invention further provides a method of delivering a heterologous gene selectively to a cell which expresses a cell surface molecule comprising the steps of 1) contacting an adenoviral particle which comprises said heterologous gene with the targeting molecule of the invention to form a complex comprising said adenoviral particle and said targeting molecule and 2) contacting said cell with said complex.

The flexibility of the targeting strategy of the invention also allows the rapid identification of cell surface molecules that are suitable to target with an adenoviral particle of the invention. Accordingly, the invention provides a method for identifying, either or both, a cell surface molecule that is suitable for mediating cell entry of an adenoviral particle to a specific cell or tissue, or a ligand that is suitable for targeting an adenoviral particle to a specific cell or tissue comprising the steps of 1) combining a ligand molecule for a cell surface molecule with a soluble adenoviral receptor molecule and a trimerization domain to form a targeting molecule, 2) contacting an adenoviral particle which comprises a marker gene with the targeting molecule to form a complex, 3) contacting a cell or tissue expressing said cell surface molecule with said complex, and 4) selecting a complex able to transduce efficiently said cell or tissue as reported by the marker gene.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows schematic representations of soluble CAR constructs. The upper diagram represents the coxsackie-adenovirus receptor (CAR), including the leader sequence (LS), the extracellular domain, the transmembrane domain (TM) and the intracellular domain (ID). The 2nd diagram represents sCAR-cRGD which comprises the extracelluar domain of CAR (sCAR) linked to a cRGD ligand. A His-tag was included at the carboxy-terminus to facilitate purification of the protein. The 3rd diagram represents sCAR-apoE which is similar to sCAR-cRGD except the apolipoproteinE (apoE) ligand replaces the cRGD ligand. The 4th diagram represents sCAR-trimer, which comprises a trimerization domain linked to the carboxy-terminus of the extracelluar domain of CAR (sCAR). The 5th diagram represents sCAR-trimer-apoE, which further comprises apoE as the targeting ligand domain.

Figure 2 shows that the adenoviral vector-sCAR complex is stable. HDFs were transduced with either unmodified Av3GFP (upper left) or Av3GFP complexed with sCAR-cRGD (upper right). Av3GFP-sCAR-cRGD complex was subjected to CsCl gradient centrifugation followed by freezing and thawing prior to transduction of HDFs (lower left). In addition to CsCl banding and freeze/thawing, the complex was exposed to serum for 60 minutes prior to transduction of HDFs (lower right). GFP fluorescence of the transduced cells shows that the complexes are stable under the tested conditions.

Figure 3 shows that trimerized versions of sCAR containing a targeting ligand domain demonstrate an enhanced ability to transduce human diploid fibroblasts (HDFs) compared to monomeric versions of sCAR containing the same targeting ligand domain. Av3GFP without the addition of a sCAR fusion protein yields 8.3 % GFP positive cells. sCAR fused

with an apoE targeting ligand domain yields efficient transduction of HDFs.

Figure 4 shows that sCAR-trimer effectively blocks liver transduction by the adenoviral vector. The monomeric version of sCAR does not block liver transduction efficiently. Group 1 mice did not receive any adenoviral vector. Group 2 mice received Av3nBg alone. Group 3 mice received Av3nBg complexed with 3 μg of sCAR trimer. Group 4 mice received Av3nBg complexed with 15 μg of sCAR trimer. Group 5 mice received Av3nBg complexed with 3 μg of sCAR monomer. Group 6 mice received Av3nBg complexed with 15 μg of sCAR monomer.

Figure 5 shows the plasmid map of pcDNA3.1.

Figure 6 shows the plasmid map of pCIneo.

Figure 7 shows that systemic delivery of oncolytic vectors using trimeric sCARt-cRGD targeting molecules reduces liver toxicity in tumor bearing mice. PC3 cell xenografts in nude mice were treated with a single intraveneous administration of Ar6pAOscE3F alone (OV) or complexed with the trimeric sCARt-cRGD targeting molecule (OV+sCARt-cRGD) at 1×10^{13} particles per kilogram or with HBSS buffer alone. Blood was collected from 5 mice per group at 24 hours, 72 hours, or 1-week post injection and serum isolated and submitted for AST and ALT serum chemistries. The average AST (A) or ALT (B) ± standard deviation is shown for each time point.

Figure 8 shows that systemic delivery of oncolytic adenoviral vectors using trimeric sCARt-cRGD targeting molecules improves efficacy. PC3 cell xenografts in nude mice were treated with a single intraveneous administration of Ar6pAOscE3F alone (OV) or complexed with the trimeric sCARt-cRGD targeting molecule (OV+sCARt-cRGD) at 1×10^{13} particles per kilogram or with HBSS buffer alone. Tumor volumes were determined twice a week.

Results are shown as the average tumor volume (mm^3) ± standard error of the mean (SEM), (n=15 per group) over time. *, p=0.028, statistically significant difference compared with HBSS or virus alone treatment groups as determined by one way analysis of variance using the Tukey's test.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a targeting strategy that employs a soluble adenoviral receptor domain domain, such as the extracellular domain of CAR (sCAR). A targeting ligand domain is appended to the soluble adenoviral receptor domain, and then the conjugate is added to an adenoviral particle. The conjugate binds to the fiber knob of the adenoviral particle to form a complex and thereby redirects the vector to a different cell surface molecule. Surprisingly, it is found that trimerization of the soluble adenoviral receptor domain significantly enhances the binding of such a targeting molecule to the adenoviral particle. Furthermore, it is surprisingly found that adenoviral particles complexed with targeting molecules which include a trimerization domain and a targeting ligand domain more efficiently transduce cells in vitro and in vivo compared to targeting molecules without a trimerization domain. This approach of re-targeting an adenoviral particle does not require the time-consuming generation of genetically modified adenoviral vectors. Adenoviral particles can be prepared and grown to high titer using normal protocols and standard cell lines. The addition of a soluble adenoviral receptor domain, such as sCAR, fused to a targeting ligand domain ablates the normal tropism of the vector and simultaneously redirects it to the target of choice.

Accordingly, the present invention provides a targeting molecule comprising a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain.

An adenoviral receptor domain may bind an adenoviral fiber protein with an affinity of for

example at least 1 µM (Kd) and preferredly with an affinity of at least 1 nM (Kd). The adenoviral receptor domain masks the physiological binding epitope of the adenoviral fiber protein such that it can no longer interact with its physiological cellular receptor. Recent data describe the critical regions on the adenoviral fiber knob responsible for binding to CAR. These data show that the binding region is located on the side of the adenoviral fiber knob (Science 286 p.1568; Science 286 p.1579). An adenoviral receptor domain within the meaning of the invention may bind an adenoviral fiber protein of any one of the serotypes of human or nonhuman adenoviruses. Preferred, however, is the receptor for the Ad2 and the Ad5 adenovirus.

A soluble adenoviral receptor domain may be a fragment or a chemically modified fragment, or even the entire part of an adenoviral receptor molecule which retains binding specificity for an adenoviral fiber protein and may be dissolved in aequeous solution under physiological conditions. Preferably, the soluble adenoviral receptor domains are isolated extracellular domains of adenoviral receptor domains. In a preferred embodiment the soluble adenoviral receptor domain is sCAR. The CAR cDNA sequence is known in the art and is published under GenBank accession number Y07593. In one embodiment of the present invention sCAR comprises at least base pairs 60 to 487 of the published CAR cDNA sequence, extending from the ATG codon through the first Ig-like domain, termed the D1 domain. A preferred sCAR-sequence of this invention includes base pairs 54 to 767 of the CAR sequence.

The trimerization domain of the targeting molecule may be a heterologous trimerization domain with respect to the soluble adenoviral receptor domain, i.e. it comprises a nonnative amino acid sequence with respect to the soluble adenoviral receptor domain. "Nonnative amino acid sequence" encompasses any amino acid sequence that is not found in the soluble adenoviral receptor domain and which is introduced into the soluble adenoviral receptor domain, for example at the level of gene expression. Nonnative

amino acid sequences include for example an amino acid sequence derived from an leucine zipper molecule, such as a yeast leucine zipper molecule. In one embodiment the nonnative amino acid sequence is a variant of the yeast leucine zipper molecule in which certain key leucine residues are mutated to isoleucine residues, such as in Harbury et al. Science 262 pp. 1401-1407 (1993). The trimerization domain confers upon the soluble adenoviral receptor domain the ability to form a trimer, in particular a homotrimer, directly or indirectly. Indirect homotrimerization may for example be achieved via a bispecific or multispecific binding agent, such as an antibody or fragment thereof, which interact with the trimerization domain.

The trimerization domain may be localized downstream of the C-terminus of the soluble adenoviral receptor domain (Figure 1, "sCAR-trimer" and "sCAR-trimer-apoE"). The trimerization domain may also be introduced into the sequence of the soluble adenoviral receptor domain. If the trimerization domain is introduced into the sequence of the soluble adenoviral receptor domain, it is preferredly introduced into the the carboxy-terminal end.

The trimerization domain of the invention may be derived in particular from the bacteriophage T4 fibritin molecule (Structure 5 p. 789, 1997), the neck region peptide from the human lung surfactant D protein (J Biol Chem 271 p.18912-18919, 1996 and J Immunol 164 p.5866-5870, 2000), a yeast heat shock transcription factor (Biochemistry 38 p.3559-3569, 1999), the trimerization domain of cartilage matrix protein (JMB 256 p. 909-923, 1996), the collagen-like tail of asymmetric acetylcholinesterase (Biochem J. 350 p.283-290, 2000), the trimer carboxyl pro-peptide of collagen I (J Biol Chem August 2, 2000), the TNFα trimerization domain (Microsc Res Tech 50 p.184-195, Aug 2000), the fusion protein of respiratory syncytial virus (J Virol 74 p.5911-5920, 2000) and procollagen (EMBO J 16 p.6694-6701, Nov 1997). In a particularly preferred embodiment the trimerization domain is the isoleucine variant of the yeast GCN4 protein (Seq. Id. No. 3: GCN4 variant DNA sequence: ATG AAA CAA ATT GAA GAC AAG ATT GAA GAA

ATT CTA TCA AAA ATT TAT CAC ATT GAA AAC GAA ATT GCC AGA ATT AAA AAA CTA ATT GGC GAA; Seq. Id. No.4: GCN4 variant amino acid sequence: MKQIEDKIEEILSKIYHIENEIARIKKLIGE) as described in Harbury et al. Science 262 pp. 1401-1407 (1993), which is hereby incorporated by reference in its entirety.

It will be readily appreciated by the person skilled in the art that important criteria for selecting a suitable trimerization domain in a particular setting are , first, its "strength" and, second, its "size". The strength of the trimerization domain may be quantified as the stability of the trimeric molecule formed under defined conditions, as measurable for example in its association / dissociation kinetics. The size of the trimerization domain (in particular the total number of amino acids of the trimerization domain) may be a criterion of choice in the construction of a particular targeting molecule because the trimerization domain should be small enough to be incorporated into the soluble adenoviral receptor domain without disrupting its binding function.

In yet another preferred embodiment the targeting molecule further comprises a linker element which is localized between the carboxy-terminal end of the adenoviral receptor domain and the trimerization domain (see Figure 1). The linker element may preferredly be a peptide linker. As used herein, the term "peptide linker" refers to a short peptide sequence serving as a spacer e.g. between the carboxy-terminal end of the adenoviral receptor domain and the trimerization domain. Such a sequence desirably is incorporated into the protein to ensure that the trimerization domains are not sterically hindered by the soluble adenoviral receptor domains and are capable to interact and efficiently form homotrimers. A linker sequence can be of any suitable length, preferably from about 3 to about 30 amino acids, and comprises any amino acids, for instance, a mixture of glycine and serine residues. Optimally, the linker sequence does not interfere with the functioning of the soluble adenoviral receptor domain. In a preferred embodiment the linker element consists of alternating glycine and serine residues.

The targeting molecule may also be assembled or combined, wholly or partly, by non-covalently binding each domain.

A targeting ligand domain of the targeting molecule of the present invention may include any cell specific attachment moiety which is suitable for the purposes of the invention. The targeting ligand domain may, for example, be selected from the group consisting of either physiological ligands, anti-receptor antibodies or cell specific peptides. The term "physiologic ligand" refers to a ligand for a cell surface receptor. Physiologic ligands and cell specific peptides derived therefrom are preferred elements of the targeting molecule of this invention.

A targeting ligand domain will selectively bind to a cell surface molecule. A targeting ligand domain "selectively binds" a cell surface molecule when it interacts with a binding domain of said cell surface molecule with a greater affinity, or is more specific for that binding domain as compared with other binding domains of other cell surface molecules. The expression "is specific for" refers to the degree of selectivity shown by a peptide or protein with respect to the number and types of interacting molecules with which the protein interacts and the rates and extent of these reactions, e.g. the degree of selectivity shown by an antibody with respect to the number and types of antigens with which the antibody combines and the rates and the extent of these reactions. The expression "selectively binds" in the present context also means binding sufficient to be useful in the method of the invention. As is known in the art, useful selective binding, for instance, to a receptor, depends on both the binding affinity and the concentration of ligand achievable in the vicinity of the receptor. Thus, binding affinities lower than that found for any naturally occurring competing ligands may be useful, as long as the cell or tissue to be treated can tolerate concentrations of added ligand sufficient to compete, for instance, for binding to a cell surface receptor.

The expression "cell surface molecule" within the meaning of the invention comprises any molecule displayed at the surface membrane of a eukaryotic cell which will selectively bind to a targeting ligand domain of the invention. By "cell surface molecule" is meant any site, i.e., a single molecule or a plurality of molecules, present on the surface of a cell with which the targeting ligand domain can interact to attach to the cell and, thereby, promote cell entry of the adenoviral particle.

A targeting ligand domain may be a fragment or a chemically modified fragment, or even the entire part of natural occurring ligand molecule specific to cell surface molecule(s).

Targeting ligands useful in the present invention include, but are not limited to, the TNF superfamily of ligands which include tumor necrosis factors (TNF's) such as, for example, TNF-alpha and TNF-beta, lymphotoxins, Fas ligand which binds to Fas antigen; CD40 ligand, which binds to the CD40 receptor of B-lymphocytes; CD30 ligand, which binds to the CD30 receptor of neoplastic cells of Hodgkin's lymphoma; CD27 ligand, NGF ligand, and OX-40 ligand; transferrin, which binds to the transferrin receptor located on tumor cells, activated T-cells, and neural tissue cells; ApoB, which binds to the LDL receptor of liver cells; alpha-2-macroglobulin, which binds to the LRP receptor of liver cells; alpha-1 acid glycoprotein, which binds to the asialoglycoprotein receptor of liver; mannose-containing peptides, which bind to the mannose receptor of macrophages; sialyl-Lewis-X antigen-containing peptides, which bind to the ELAM-1 receptor of activated endothelial cells; CD34 ligand, which binds to the CD34 receptor of hematopoietic progenitor cells; ICAM-1, which binds to the LFA-1 (CD11b/CD18) receptor of lymphocytes, or to the Mac-1 (CD11a/CD18) receptor of macrophages; M-CSF, which binds to the c-fms receptor of spleen and bone marrow macrophages; circumsporozoite protein, which binds to hepatic Plasmodium falciparum receptor of liver cells; VLA-4, which binds to the VCAM-1 receptor of activated endothelial cells; LFA-1, which binds to the ICAM-1 receptor of activated endothelial cells;

NGF, which binds to the NGF receptor of neural cells; HIV gp120 and Class II MHC antigen, which bind to the CD4 receptor of T-helper cells; the LDL receptor binding region of the apolipoprotein E (ApoE) molecule; colony stimulating factor, or CSF, which binds to the CSF receptor; insulin-like growth factors, such as IGF-I and IGF-II, which bind to the IGF-I and IGF-II receptors, respectively; interleukins 1 through 18 which bind to the interleukin 1 through 18 receptors, respectively; and the Fv antigen-binding domain of an immunoglobulin.

In one preferred embodiment the targeting ligand domain is chosen from FGF-2 (also known as basic fibroblasts growth factor-2) and EGF (epidermal growth factor). These targeting ligand domains are useful to target tumors.

In a further embodiment the targeting ligand domain is a single chain antibody fragment (scFv) targeting ligand domain. In particular the scFv may recognize cc39, which is a tumor specific marker. Accordingly this embodiment of the invention provides a further means to specifically target tumors.

In another preferred embodiment the targeting ligand domain is polylysine. Polylysine binds to heparan sulfate proteoglycans and is useful for locoregional delivery to tumors, i.e the choice of polylysine as the targeting ligand domain will enhance the infection of tumor cells throughout a tumor mass if the vector is locally injected into a tumor mass.

In a particular embodiment of this invention, the targeting ligand domain is cyclic RGD, which has the amino acid sequence CDCRGDCFC (Seq. Id. No.5). The cRGD ligand binds selectively to avß3 and avß5 integrins. Such integrins are found in abundance on proliferating endothelial cells, which are present in tumor blood vessels. It has been shown that cRGD homes to several tumor types, including carcinoma, sarcoma, and melanoma. Published data suggest that cRGD targets not only the tumor vasculature but

also certain tumor cells themselves.

In a another preferred embodiment the targeting ligand domain includes at least 15 amino acids derived from an apoE protein. More preferred is a targeting molecule wherein the targeting ligand domain includes two tandem copies of amino acids 141-155 derived from an apoE protein (Seq. Id. No.6: apoE dimer DNA sequence: CTG CGC AAG CTG CGT AAG CGG CTC CTC CGC GAT GCC GAT GAC CTG CTG CGC AAG CTG CGT AAG CGG CTC CTC CGC GAT GCC GAT GAC CTG ; Seq. Id. No.7: apo E dimer amino acid sequence: LRKLRKRLLRDADDL LRKLRKRLLRDADDL). The apoE ligand binds to receptors of the LDL-receptor family, which are found on hepatocytes, and, thus the ligand may be useful in liver gene therapy applications. Two tandem copies of the region of apolipoprotein E which recognizes the LDL receptor are used because it has been shown that this structure is required to generate an appropriate configuration for binding activity when the peptide is removed from its normal context.

In a further preferred embodiment of the present invention, the targeting ligand domain is conjugated to the carboxy-terminus of the soluble adenoviral receptor domain, either by covalent or non-covalent binding. Preferredly, the targeting molecule further comprises a linker element which is localized between the carboxy-terminal end of the trimerization domain and the targeting ligand domain. Preferredly, the linker inserted between the soluble adenoviral receptor domain and the trimerization domain is different in its amino acid sequence from the linker inserted between the trimerization domain and the targeting ligand domain in order to prevent homologies in the DNA construct encoding such a targeting molecule. Such homologies are disadvantageous because they may cause instability due to homologous recombination at the DNA level.

The present invention also provides a trimeric targeting molecule comprising the targeting molecule of the invention. The trimeric targeting molecule assembles due to the

trimerization domain which has been introduced into the monomeric targeting molecule.

The present invention further provides a complex comprising an adenoviral particle and the targeting molecule. A "complex" of the adenoviral particle and the targeting molecule is any interaction, e.g., covalent or noncovalent, between the adenoviral particle and the targeting molecule. Preferably, it is a noncovalent interaction. Complex formation occurs when the adenoviral particle and the targeting molecule are contacted. Such "contacting" can be done by any means known to those skilled in the art and described herein, by which the mutual tangency of the adenovirus and targeting molecule can be effected. For instance, contacting of the adenoviral particle and the targeting molecule can be done by mixing these elements in a small volume of the same solution. For example, the adenoviral particle and the targeting molecule can be allowed to associate for 30 minutes at 37°C in a suitable solution. Optionally, the adenoviral particle and the targeting molecule further can be covalently joined, e.g., by chemical means known to those skilled in the art, or other means, or, preferably, can be linked by means of noncovalent interactions (e.g., ionic bonds, hydrogen bonds, van der Waals forces, and/or nonpolar interactions). Preferredly, the complex of the adenovirus and the targeting molecule is formed prior to the contacting of the cell. This period of time may be about as long as the maximum length of time a complex of an adenovirus and a targeting molecule can be stably maintained in a useable form, for instance, lyophilized, or in the presence of cryoprotective agents at –80°C.

The present invention also provides a polynucleotide encoding the amino acid sequence of the targeting molecule of the invention. Also provided is a polynucleotide that is a variant of such a polynucleotide and encodes a corresponding functional variant of the amino acid sequence of the targeting molecule. A functional variant may differ in amino acid sequence by one or more substitutions, additions, deletions, truncations which may be present in any combination, but would retain the same biological function as the

referee targeting molecule.

Among preferred variants are those that vary from a reference polypeptide by conservative amino acid substitutions. Accordingly, the present invention also contemplates a polynucleotide encoding the amino acid sequence of the targeting molecule and any polynucleotide that is a conservatively modified variant of such a polynucleotide. A "conservatively modified variant" is a variation on the nucleic acid sequence that results in a conservative amino acid substitution. A "conservative amino acid substitution" is an amino acid substituted by an alternative amino acid of similar charge density, hydrophilicity/hydrophobicity, size, and/or configuration. In comparison, a "nonconservative amino acid substitution" is an amino acid substituted by an alternative amino acid of differing charge density, hydrophilicity/hydrophobicity, size, and/or configuration. The means of making such modifications are well known in the art.

The following non-limiting list of amino acids are considered conservative replacements: a) alanine, serine, and threonine; b) glutamic acid and asparatic acid; c) asparagine and glutamine d) arginine and lysine; e) isoleucine, leucine, methionine and valine and f) phenylalaine, tyrosine and tryptophan.

"Biological function" within the meaning of this application is to be understood in a broad sense. It includes, but is not limited to, the particular functions of the elements of the targeting molecule disclosed in this application, the element being the soluble adenoviral receptor domain, the trimerization domain and the targeting ligand domain. Thus, biological functions are not only those which a polypeptide displays in its physiological context, i.e. as part of a living organism or cell, but includes functions which it may perform in a non-physiological setting, e.g. in vitro. For example, a biological function of the soluble adenoviral receptor domain within the meaning of this application is the ability to bind to the fiber protein of an adenoviral particle of the invention either in vitro or in

vivo. A biological function of the trimerization domain within the meaning of this application is the ability to trimerize the targeting molecule of the invention in vitro and to maintain the trimeric state in vivo. A biological function of the targeting ligand domain within the meaning of this application is the ability to bind to a corresponding cell surface molecule as defined in this application in vitro or in vivo. Assays to assess the required properties, for example the binding properties of the proteins to specific ligands are well-known in the art.

The means of making such a targeting molecule, in particular the means of introducing the sequence of the trimerization domain into the sequence of the soluble adenoviral receptor domain or at the 3' end of the soluble adenoviral receptor domain at the level of DNA, is well known in the art, and is further described in the examples of the present invention. Briefly, the method comprises introducing a sequence of the chosen trimerization domain into the sequence encoding the chosen soluble adenoviral receptor domain so as to insert a new peptide motif into or in place of a protein sequence of the wild-type soluble adenoviral receptor domain. Such introduction can result in the insertion of a new peptide binding motif, or creation of a peptide motif, e.g. wherein some of the sequence comprising the motif is already present in the wild-type soluble adenoviral receptor domain. The method also can be carried out to replace sequences of the soluble adenoviral receptor domain with a nonnative amino acid sequence according to the invention. Generally, this can be accomplished by cloning the nucleic acid sequence encoding the soluble adenoviral receptor domain into a plasmid or some other vector for ease of manipulation of the sequence. Then, a unique restriction site at which further sequences can be added is identified or inserted into the sequence of the plasmid including the sequence of the soluble adenoviral receptor domain. A double-stranded synthetic oligonucleotide generally is created from overlapping synthetic single-stranded sense and antisense oligonucleotides such that the double-stranded oligonucleotide incorporates the restriction sites flanking the target sequence and, for instance, can be

used to incorporate replacement DNA. The plasmid or other vector is cleaved with the restriction enzyme, and the oligonucleotide sequence having compatible cohesive ends is ligated into the plasmid or other vector to replace the wild-type DNA. Other means that are known to those skilled in the art, in particular using PCR techniques, can also be used to introduce the sequence of the trimerization domain into the soluble adenoviral receptor domain coding sequence.

In one preferred embodiment, the trimerization domain sequence is cloned so as to be located at the 3' end of the sequence encoding the soluble adenoviral receptor domain. Further details of the cloning approaches provided by this invention are provided in the examples below.

The invention further provides an expression vector comprising a polynucleotide encoding the nucleic acid sequence of the targeting molecule, or comprising at least two polynucleotides encoding for a ligand molecule and a soluble adenoviral receptor molecule optionally further comprising in sequence a trimerization domain. A suitable expression vector is any vector that includes all necessary genetic elements for the expression of the inserted DNA sequence when propagated in a suitable host cell. Numerous suitable expression vectors are known to the person skilled in the art and are commercially available.

The present invention provides a complex comprising an adenoviral particle and the targeting molecule. The term "adenoviral particle" is to be understood broadly as meaning infectious viral particles that are formed when an adenoviral vector of the invention is transduced into an appropriate cell or cell line for the generation of infectious particles. The term "adenoviral vector" includes recombinant adenoviral vectors. Recombinant adenoviral vectors may be generated by a variety of techniques. Such techniques include introducing a desired gene of interest into a bacterial plasmid at a site flanked by

adenovirus sequences. These sequences provide control elements for gene expression and serve as sites for recombination with a compatible adenoviral genome when cotransfected together into an appropriate mammalian cell line (Horwitz, M. S., "Adenoviruses," in Fields Virology, Third Edition, edited by B. N. Fields, D. M. Knipe, P. M. Howley et al., Lippincott-Raven Publishers: Philadelphia, Pa. (1996)).

The adenoviral vector which is employed may, in one embodiment, be an adenoviral vector which includes essentially the complete adenoviral genome. (Shenk, et al., Curr. Top. Microbiol. Immunol., (1984); 111(3):1-39). Alternatively, the adenoviral plasmid vector may be a modified adenoviral vector in which at least a portion of the adenoviral genome has been deleted.

In one embodiment, the vector comprises an adenoviral 5' ITR; an adenoviral 3' ITR; an adenoviral encapsidation signal; at least one DNA sequence encoding a therapeutic agent(s); and a promoter controlling the DNA sequence(s) encoding a therapeutic agent(s). The vector is free of at least the majority of adenoviral E1 and E3 DNA sequences, but is not free of all of the E2 and E4 DNA sequences, and DNA sequences encoding adenoviral proteins promoted by the adenoviral major late promoter. In one embodiment, the vector is also free of at least a portion of at least one DNA sequence selected from the group consisting of the E2 and E4 DNA sequences. In another embodiment, the vector is free of at least the majority of the adenoviral E1 and E3 DNA sequences, and is free of one of the E2 and E4 DNA sequences, and is free of a portion of the other of the E2 and E4 DNA sequences.

In yet another embodiment, the adenoviral vector is free of at least the majority of the E1 and E3 DNA sequences, is free of at least a portion of at least one DNA sequence selected from the group consisting of the E2 and E4 DNA sequences, and is free of DNA sequences encoding adenoviral proteins promoted by the adenoviral major late promoter.

Such an adenoviral vector may be constructed first by constructing, according to standard techniques, a shuttle plasmid which contains, beginning at the 5' end, the "critical left end elements," which include an adenoviral 5' ITR, an adenoviral encapsidation signal, and an E1a enhancer sequence; a promoter (which may be an adenoviral promoter or a foreign promoter); a tripartite leader sequence, a multiple cloning site (which may be as hereinabove described); a poly A signal; and a DNA segment which corresponds to a segment of the adenoviral genome. Such DNA segment serves as a substrate for homologous recombination with a modified or mutated adenovirus, and such sequence may encompass, for example, a segment of the adenovirus 5 genome no longer than from base 3329 to base 6246 of the genome. The plasmid may also include a selectable marker and an origin of replication. The origin of replication may be a bacterial origin of replication. A desired DNA sequence encoding a therapeutic agent may then be inserted into the multiple cloning site. Homologous recombination is then effected with a modified or mutated adenovirus in which at least the majority of the E1 and E3 adenoviral DNA sequences have been deleted. Such homologous recombination may be effected through co-transfection of the shuttle plasmid and the modified adenovirus into a helper cell line, such as 293 cells, by $CaPO_4$ precipitation. Upon such homologous recombination, a recombinant adenoviral vector is formed which includes DNA sequences derived from the shuttle plasmid between the Not I site and the homologous recombination fragment, and DNA derived from the E1 and E3 deleted adenovirus between the homologous recombination fragment and the 3' ITR. The homologous recombination fragment preferredly overlaps with nucleotides 3329 to 6246 of the adenovirus 5 genome.

Through such homologous recombination, an adenoviral vector may be formed which includes an adenoviral 5' ITR, an adenoviral encapsidation signal; an E1a enhancer sequence; a promoter; a tripartite leader sequence; at least one DNA sequence encoding a therapeutic agent; a poly A signal; adenoviral DNA free of at least the majority of the E1 and

E3 adenoviral DNA sequences; and an adenoviral 3' ITR. This vector may then be transfected into a helper cell line, such as the 293 helper cell line, which will include the E1a and E1b DNA sequences, which are necessary for viral replication, and to generate infectious viral particles.

The adenoviral vector is transfected into an appropriate cell line for the generation of adenoviral particles. Transfection may take place by electroporation, calcium phosphate precipitation, microinjection, or through proteoliposomes. Examples of appropriate cell lines include, but are not limited to, HeLa cells or 293 (embryonic kidney epithelial) cells.

In another embodiment, the adenoviral vector comprises an adenoviral 5' ITR; an adenoviral 3' ITR; an adenoviral encapsidation signal; at least one DNA sequence encoding a therapeutic agent; and a promoter controlling the at least one DNA sequence encoding a therapeutic agent. The vector is free of the adenoviral E1, E2, E3, and E4 DNA sequences, and the vector is free of DNA sequences encoding adenoviral proteins promoted by the adenoviral major late promoter.

Such vectors may be constructed by removing the adenoviral 5' ITR, the adenoviral 3' ITR, and the adenoviral encapsidation signal, from an adenoviral genome by standard techniques. Such components, as well as a promoter (which may be an adenoviral promoter or a non-adenoviral promoter), tripartite leader sequence, poly A signal, and selectable marker, may, by standard techniques, be ligated into a base plasmid or "starter" plasmid such as, for example, pBluescript II KS-(Stratagene), to form an appropriate cloning vector. The cloning vector may include a multiple cloning site to facilitate the insertion of DNA sequence(s) encoding therapeutic agent(s) into the cloning vector. In general, the multiple cloning site includes "rare" restriction enzyme sites; i.e., sites which are found in eukaryotic genes at a frequency of from about one in every 10,000 to about one in every 100,000 base pairs. An appropriate vector is thus formed by cutting the cloning vector by

standard techniques at appropriate restriction sites in the multiple cloning site, and then ligating the DNA sequence encoding a therapeutic agent(s) into the cloning vector.

The vector may be packaged into infectious viral particles using a helper adenovirus which provides the necessary encapsidation materials. Preferably the helper virus has a defective encapsidation signal in order that the helper virus will not encapsidate itself. An example of an encapsidation defective helper virus which may be employed is described in Grable, et al., J. Virol., Vol. 66, pgs. 723-731 (1992).

The present invention also provides a method of targeting an adenoviral particle to a cell which expresses a cell surface molecule comprising the steps of contacting said adenoviral particle with a targeting molecule which comprises a soluble adenoviral receptor domain, a trimerization domain and a targeting ligand domain, obtaining a complex suitable to target said cell surface molecule and contacting said cell with said complex.

The present invention further provides a method of delivering an adenoviral vector selectively to a cell which expresses a cell surface molecule comprising the steps of contacting an adenoviral particle which comprises said adenoviral vector with a targeting molecule which comprises a soluble adenoviral receptor domain, a trimerization domain and a targeting ligand domain, obtaining a complex suitable to target said cell surface molecule, and contacting said cell with said complex.

Furthermore, the targeting molecules of the invention are useful to conveniently assess whether a cell surface molecule is capable of mediating cell entry of the adenoviral particle. One advantage of targeting vectors via sCAR is that it circumvents the need to generate modified vectors for each new target. In contrast, targeting strategies based on insertion of a targeting ligand domain into a capsid protein, such as fiber or hexon, or

penton require the generation of a new adenoviral vector for each ligand to be tested. In addition, capsid protein modification strategies rely on a mechanism to ablate the normal tropism of the virus, such as generating mutations in the fiber knob to knockout CAR binding ability. However, ablation of CAR binding may adversely affect the entry of vector into packaging cells, requiring further manipulation of either the packaging cells or the virus to enable production of vector. The sCAR targeting strategy does not require manipulation of the virus or the packaging cells, so vectors can be grown to normal titers on standard packaging cells. In addition, the sCAR strategy simultaneously ablates the normal tropism of the vector and redirects it to a new target.

Thus, the present invention provides a convenient method to screen targeting ligand domains in cell culture. Numerous potential ligands can be inserted into the expression plasmid encoding sCAR and the corresponding fusion proteins can be generated conveniently. Each one can be complexed with an adenoviral vector encoding a marker gene, such as for example GFP, and the transduction efficiency of specific target cells can be rapidly assessed. Once the best ligands are identified, they may also be employed in other vector targeting strategies, such as the insertion of ligands into exposed loops of capsid proteins.

The present invention also provides a method of identifying a cell surface molecule that is suitable to mediate entry of an adenoviral particle to a specific cell or tissue expressing said cell surface molecule, comprising the steps of, producing a targeting molecule comprising a targeting ligand domain that interacts with said cell surface molecule, contacting an adenoviral particle which comprises a marker gene with the targeting molecule to form a complex, contacting said cell or tissue with said complex, and selecting a complex having efficiently transduced said cell or tissue as reported by the marker gene. Assessing the presence of said marker gene in said cell or tissue is sufficient for demonstrating efficient transduction. The "marker gene" may be any gene

carried by the adenoviral vector, whether it is a part of adenoviral origin or heterologous, that can be monitored, e.g. by assessing the expression of the gene in a cell. Numerous useful methods to assess gene expression are known to the person skilled in the art.

Furthermore, the present invention also provides a method of delivering a heterologous gene selectively to a cell which expresses a cell surface molecule comprising the steps of contacting an adenoviral particle which comprises said heterologous gene with a targeting molecule which comprises a soluble adenoviral receptor domain, a trimerization domain and a targeting ligand domain, obtaining a complex which is suitable for targeting said cell surface molecule and contacting said cell with said complex.

Accordingly, the complexes of the invention may be administered in vivo to a host. The host may be an animal host, including mammalian hosts, primate hosts and human hosts. Thus, the complex of the invention is useful as a medicament and useful for the preparation of a medicament for the treatment of a disease in a mammal including a human.

The complex of the invention may be administered in an amount effective to provide a therapeutic effect in a host. In one embodiment, the vector may be administered in an amount of from 1 plaque forming unit to about 10^{14} plaque forming units, preferably from about 10^{6} plaque forming units to about 10^{13} plaque forming units. The host may be a human or non-human animal host. Preferably, the complex particles are administered systemically, such as, for example, by intravenous administration (such as, for example, portal vein injection or peripheral vein injection), intramuscular administration, intraperitoneal administration, or intranasal administration. The complex particles may be administered in combination with a pharmaceutically acceptable carrier suitable for administration to a patient. The carrier may be a liquid carrier (for example, a saline solution), or a solid carrier, such as, for example, microcarrier beads. The complex particles, travel directly to the

desired cells or tissues upon the in vivo administration of such complex particles to a host. The targeted vector particles then infect the desired cell or tissues. Desired cells or tissues may, for example, be malignant cells and cancer tissue. Accordingly, the targeted vector particles are useful for the treatment of a disease such as for example cancer. For example, in one preferred embodiment the targeted vector particles are useful to treat prostate cancer such as, for example, adenocarcinoma of the prostate. Due to the re-targeting of the particles the side effects of the gene therapy may be reduced in such a method of treatment. In particular, the side effect of adenoviral liver toxicity may be reduced when complexes of the invention, rather than uncomplexed adenoviral vectors, are employed.

Cells which may be infected by the infectious complex particles include, but are not limited to, primary cells, such as primary nucleated blood cells, such as leukocytes, granulocytes, monocytes, macrophages, lymphocytes (including T-lymphocytes and B-lymphocytes), totipotent stem cells, and tumor infiltrating lymphocytes (TIL cells); bone marrow cells; endothelial cells; including activated endothelial cells; epithelial cells; keratinocytes; stem cells; hepatocytes, including hepatocyte precursor cells; fibroblasts; mesenchymal cells; mesothelial cells; parenchymal cells; vascular smooth muscle cells; brain cells and other neural cells; gut enterocytes; gut stem cells; and myoblasts. Cells which may be infected further include primary and metastatic cancer cells, including, but not limited to prostate, pancreatic, lung, including both small cell and non-small cell lung cancers, colon, and liver cancers. The cell which is "targeted" or infected or transduced with the infectious viral particles is dependent upon the ligand with which the targeting molecule has been engineered.

Accordingly, complexes of the invention are "targetable," i.e., the complexes, upon administration to the host, will bind to and infect a desired target cell or tissue, and thereby

deliver DNA encoding a therapeutic agent selectively to the desired target cell or tissue. The particular target cell or tissue to which the particles are targeted is dependent upon the ligand with which the targeting molecule is engineered, as the targeting ligand domain of the targeting molecule is specific for a cell surface molecule displayed by a desired target cell.

The present invention therefore also provides a method of targeting an adenovirus to a cell in order to accomplish cell entry of the adenoviral vector. The method comprises contacting the cell with a complex as described above such that entry of the adenovirus into the cell is effected. By "targeting" or "delivering selectively" it is meant to preferentially introduce into a particular cell rather than into another cell. According to the invention, a cell can be any cell, and, preferably, is a eukaryotic cell. Preferably, the eukaryotic cell is of a multicellular species, and, even more preferably, is a mammalian, e.g. human, cell. Desirably, such a eukaryotic cell is one in which an adenovirus can exist for a period of time (i.e., typically from anywhere up to, and potentially even after, about two months) after entry into the cell. Nascent RNA is transcribed from the adenoviral genome, which may include a nonnative gene, carried into the cell by the adenovirus, as further described herein.

A cell can be present as a single entity, or can be part of a larger collection of cells. Such a "larger collection of cells" can comprise, for instance, a cell culture (either mixed or pure), a tissue, e.g., epithelial or other tissue such as a neoplastic (benign or malign) tissue, an organ (e.g., heart, lung, liver and other organs), an organ system (e.g., circulatory system, respiratory system, gastrointestinal system, or other organ system), or an organism (e.g., a bird, mammal, or the like). In one embodiment , the cells being targeted are of the circulatory system (e.g., including, but not limited to heart, blood vessels, and blood), respiratory system (e.g., nose, pharynx, larynx, trachea, bronchi, bronchioles, lungs, and the like) or the gastrointestinal system (e.g., including mouth, pharynx, esophagus, stomach, intestines, salivary glands, pancreas, liver, gallbladder,

and others). In a preferred embodiment cells of neoplastic tissue (i.e. 'tumor tissue') are targeted with the targeting molecule/adenoviral particle complex of the invention.

A cell to which a recombinant adenovirus is targeted differs from another cell, which is not targeted, in that the cell being targeted displays a particular cell surface molecule or at least a higher density of a particular cell surface molecule than a non-target cell. The cell surface molecule may be a protein (including a modified protein), a carbohydrate, a glycoprotein, a proteoglycan, a lipid, a mucin molecule or mucoprotein, and the like. Examples of potential cell surface molecules include, but are not limited to heparin and chondroitin sulfate moieties found on glycosaminoglycans; sialic acid moieties found on mucins, glycoproteins, and gangliosides; major histocompatability complex I glycoproteins; common carbohydrate molecules found in membrane glycoproteins, including mannose, N-acetyl-galactosamine, N-acetyl-glucosamine, fucose, and galactose; glycoproteins such as ICAM-1, VCAM, E-selectin, P-selectin, L-selectin, and integrin molecules; and tumor-specific antigens present on cancerous cells, such as, for instance, MUC-1 tumor-specific epitopes and the cc39 molecule. The targeting of tumor-specific antigens present on cancerous cells is one preferred embodiment of this invention. However, the present method of targeting an adenovirus to a cell is not limited to any specific mechanism of cellular interaction (i.e., interaction with a given cell surface binding site), and is not to be so construed.

The adenoviral particle complexed with the targeting molecules and including a gene encoding a desired protein or therapeutic agent may be employed to infect a desired cell line in vitro, whereby the infected cells produce a desired protein or therapeutic agent in vitro. The infected cells may be useful in the treatment of a variety of diseases ("ex vivo gene therapy") including but not limited to adenosine deaminase deficiency, sickle cell anemia, thalassemia, hemophilia, diabetes, α-antitrypsin deficiency, brain disorders such as Alzheimer's disease, phenylketonuria and other illnesses such as growth disorders and

heart diseases, for example, those caused by alterations in the way cholesterol is metabolized and defects of the immune system. The targeting molecules and complexes of the invention are also useful for the extracorporal transduction of blood vessels and organs, for example in the setting of transplantation applications of gene therapy, as well as in ex vivo cell therapy.

In a particularly preferred embodiment, oncolytic adenoviral particles are contemplated as the adenoviral particles of the invention. Oncolytic adenoviral particles are adenoviral particles which selectively replicate in tumor cells and destroy the cells in which they replicate, but do not replicate in non-tumor cells. They may or may not include a heterologous gene in addition to the adenoviral elements necessary for replication. In one embodiment oncolytic adenoviral particles include a mutation in a gene essential for adenoviral replication, such as the E1a or E1b genes. Such mutations may render adenoviral replication specific for tumor tissue, e.g. if the cells of said tissue have a defect in the p53 or Rb pathways. In another embodiment the oncolytic adenoviral particles may include a tissue-specific transcritional regulatory sequence driving an adenoviral gene essential for replication of the adenoviral particle, which provides for tumor-tissue specific replication of the oncolytic adenoviral particles. See U.S. Patent No. 5,998,205, issued December 7, 1999 to Hallenbeck, *et al.*

In one aspect, the present invention provides a complex wherein the adenoviral particle includes a heterologous gene. The term "heterologous gene" means any gene that is not found in the corresponding naturally occurring (i.e. wild-type) adenovirus. The nonnative gene can be any gene, and desirably is either a therapeutic gene or a reporter gene, which, preferably, is capable of being expressed in a cell entered by the adenoviral particle. A therapeutic gene can be one that exerts its effect at the level of RNA or protein. For instance, a protein encoded by a therapeutic gene can be employed in the treatment of an inherited disease, e.g., the use of a cDNA encoding the cystic fibrosis

transmembrane conductance regulator in the treatment of cystic fibrosis. Further, the protein encoded by the therapeutic gene can exert its therapeutic effect by causing cell death. For instance, expression of the protein, itself, can lead to cell death, as with expression of diphtheria toxin A, or the expression of the protein can render cells selectively sensitive to certain drugs, e.g., expression of the Herpes simplex thymidine kinase gene renders cells sensitive to antiviral compounds, such as acyclovir, gancyclovir and FIAU (1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosil)-5-iodouracil). Alternatively, the therapeutic gene can exert its effect at the level of RNA, for instance, by encoding an antisense message or ribozyme, a protein that affects splicing or 3' processing (e.g. polyadenylation), or a protein that affects the level of expression of another gene within the cell, e.g. by mediating an altered rate of mRNA accumulation, an alteration of mRNA transport, and/or a change in post-transcriptional regulation. Thus, the use of the term "therapeutic gene" is intended to encompass these and any other embodiments of that which is more commonly referred to as gene therapy as known to those of skill in the art. The term "therapeutic agent" is used in a generic sense and includes treating agents, prophylactic agents, and replacement agents.

DNA sequences encoding therapeutic agents which may be placed into the adenoviral vector include, but are not limited to, DNA sequences encoding tumor necrosis factor genes, such as TNF-α; genes encoding interferons such as interferon-α, interferon-ß, and interferon-γ; genes encoding interleukins such as IL-1, IL-1ß, and interleukins 2 through 18; genes encoding GM-CSF; genes encoding adenosine deaminase, or ADA; genes which encode cellular growth factors, such as lymphokines, which are growth factors for lymphocytes; genes encoding soluble CD4; Factor VIII; Factor IX; T-cell receptors; the LDL receptor, ApoE, ApoC,ApoAI and other genes involved in cholesterol transport and metabolism; the alpha-1 antitrypsin gene, the ornithine transcarbamylase gene, the CFTR gene, the insulin gene, negative selective markers or "suicide" genes, such as viral thymidine kinase genes, such as the Herpes Simplex Virus thymidine kinase gene, the

cytomegalovirus virus thymidine kinase gene, and the varicella-zoster virus thymidine kinase gene; Fc receptors for antigen-binding domains of antibodies, and antisense sequences which inhibit viral replication.

In a preferred embodiment of the invention the DNA sequence encoding the therapeutic agent is selected from either GM-CSF, thymidine kinase, Nos, FasL, or sFasR (soluble Fas receptor). The DNA sequence encoding the therapeutic agent may also be a sequence which is a part of the adenoviral genome, such as the adenoviral E1a gene. On one hand, E1a is instrumental in driving the adenoviral replication cycle, which in turn leads to cell lysis. Accordingly, E1a may be considered a DNA sequence encoding the therapeutic agent within the meaning of the invention, if administered to e.g a tumor tissue. Furthermore, such genes may provide an additional therapeutical benefit, e.g. by sensitizing the infected cell to certain agents and/or radiation.

For human patients, the therapeutic gene will generally be of human origin although genes of closely related species that exhibit high homology and biologically identical or equivalent function in humans may be used if the gene does not produce an adverse immune reaction in the recipient. A therapeutic active amount of a nucleic acid sequence or a therapeutic gene is an amount effective at dosages and for a period of time necessary to achieve the desired result. This amount may vary according to various factors including but not limited to sex, age, weight of a subject, and the like.

The DNA sequence encoding at least one therapeutic agent is under the control of a suitable promoter. Suitable promoters which may be employed include, but are not limited to, adenoviral promoters, such as the adenoviral major late promoter; or hetorologous promoters, such as the cytomegalovirus (CMV) promoter; the Rous Sarcoma Virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; and the ApoAI promoterThe following tumor

selective promoters are preferred embodiments of this invention: E2F, osteocalcin, L-plastin, CEA, AVP, c-myc, telomerase, skp-2, psma, cyclin A, and cdc25 promoters. In a particularly preferred embodiment the promoter of the invention is the E2F promoter. In one embodiment of this invention the E2F promoter is operatively linked to the E1a gene. It is to be understood, however, that the scope of the present invention is not to be limited to specific foreign genes or promoters.

EXAMPLES

The invention will now be described with respect to the following examples; it is to be understood, however, that the scope of the present invention is not intended to be limited thereby.

Example 1: Isolation of human cDNA encoding CAR

The human cDNA encoding CAR was cloned by RT-PCR. The published CAR cDNA sequence (GenBank accession number Y07593) was used to design oligonucleotide primers for amplification. Total RNA was isolated from cultured HeLa cells using RNAzol (Tel-Test, Friendswood, TX) and 1 µg was reverse transcribed using an RT-PCR system (Perkin Elmer). Primers were designed to amplify the entire coding sequence of the full-length CAR cDNA starting from the start codon, ATG, and ending with the termination codon, TAG. For cloning purposes, the sense primer contained a BamHI restriction site and a Kozak consensus sequence (5'-GTAGGATCCGCCACCATGGCGCTCCTGCTG-3' (Seq. Id. No.8)). The antisense primer contained an EcoRI restriction site (5'-GCGCGAATTCCTATACTATAGACCCATCCT-3' (Seq. Id. No.9)). A 1.1 kb amplified product of the expected size was obtained and cloned into pcDNA3.1 (Invitrogen, San Diego, CA; Figure 5) to generate the plasmid pcDNAhCAR. The nucleotide sequence of the cloned insert was determined and two individual basepair changes were identified in

the intracellular domain. The first basepair change was silent and did not result in an amino acid change. The second basepair change resulted in a serine to asparagine amino acid change. The CAR extracellular domain was of the expected sequence.

Example 2: Construction of recombinant plasmids encoding sCAR

To generate a plasmid expressing human sCAR with a histidine tag at the carboxy-terminus, sequences encoding the extracellular domain of CAR were amplified by PCR from the pcDNAhCAR construct containing the entire CAR cDNA, described above. The sense primer contained an NheI site upstream of the ATG start codon and consisted of the sequence 5'-ACTAGCTAGCGCCGCCACCATGGCGCTC-3' (Seq. Id. No. 10). The antisense primer encoded the end of the extracellular domain of CAR immediately followed by an XhoI site (to allow insertion of targeting ligand domains), a 6-his tag, a TAG stop codon, and an XbaI restriction site and consisted of the sequence 5'-GTGATCTAGACTAGTGATGATGGTGATGGTGCTCGAGAGCTTTATTTGAAGGAGGG-3' (Seq. Id. No. 11). The PCR product was analyzed by agarose gel electrophoresis, digested with NheI and XbaI, and ligated into the NheI and XbaI sites of the mammalian expression vector pCI-neo (Promega) to generate the plasmid pCI-neo-sCARa.

To permit insertion of targeting ligand domains at the end of sCAR, the following modifications were made to pCI-neo-sCARa. First, the NotI site in the multiple cloning region was destroyed by restriction digestion with NotI followed by blunting with T4 DNA polymerase and religating. Second, a pair of complementary oligonucleotides were synthesized and annealed to form a DNA duplex. The annealed oligonucleotides contained XhoI compatible overhangs at both ends and encoded a linker domain, to provide better presentation of the targeting ligand domain to its receptor, followed by a NotI restriction site, for insertion of ligands, and a factor Xa cleavage site, to permit removal of the his tag. The sequences of the oligonucleotides were as follows: 5'-

TCGAACCATCAGCCTCCGCATCTGCTTCCGCCCCTGGATCCGCGGCCGCCATTGAG GGCCGCC-3' (Seq. Id. No. 12) and 5'-TCGAGGCGGCCCTCAATGGCGGCCGCGGATCCAGGGGCGGAAGCAGATGCGGAG GCTGATGGT-3' (Seq. Id. No. 13). The annealed oligonucleotides were ligated into the XhoI site of pCI-neo-sCARa to generate the plasmid pCI-neo-sCARb.

To construct expression plasmids encoding targeting ligand domains at the carboxy-terminus of sCAR, pairs of complementary oligonucleotides were synthesized and annealed to form a DNA duplex encoding the desired targeting ligand domains. The DNA duplexes were designed to contain NotI compatible overhangs on both ends so the fragment could be inserted into the NotI site of pCI-neo-sCARb. Two different targeting ligand domains were fused to the end of sCAR. One ligand consists of the amino acid sequence CDCRGDCFC and is termed cyclic RGD (cRGD). The oligonucleotides that were synthesized to generate cRGD were as follows; 5'-GGCCTGCGATTGCCGTGGTGATTGCTTTTGCGC-3' (Seq. Id. No. 14) and 5'-GGCCGCGCAAAAGCAATCACCACGGCAATCGCA-3' (Seq. Id. No. 15). The resulting plasmid was designated pCI-neo-sCAR-cRGD. The second targeting ligand domain consists of two tandem copies of amino acids 141-155 derived from apolipoproteinE (apoE) which binds to receptors of the LDL-receptor family. The oligonucleotides that were synthesized to generate the apoE targeting ligand domain were as follows: 5'-GGCCCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGGC-3' (Seq. Id. No. 16) and 5'-GGCCGCCAGGTCATCGGCATCGCGGAGGAGCCGCTTACGCAGCTTGCGCAG-3' (Seq. Id. No. 17). The resulting plasmid was designated pCI-neo-sCAR-apoE. A diagram of the structures encoded by pCI-neo-sCAR-cRGD and pCI-neo-sCAR-apoE is shown in Figure 1.

Plasmids encoding trimerized sCAR were constructed as follows. First a pair of

complementary oligonucleotides were synthesized and annealed to form a DNA duplex. The duplex contained XhoI compatible overhangs on each end and also encoded a glycine/serine linker element followed by a NotI site then a factor Xa cleavage site. The duplex was ligated into the XhoI site of pCIneosCARa, described above, to generate the plasmid pCIneosCARNot. The oligonucleotides were designed such that the 5' XhoI site was destroyed, however, the 3' site remained intact. The sequences of the complementary oligonucleotides were as follows: 5' TCG AAG GAG GAG GAG GAA GTG GAG GAG GAG GAA GTG GAG GAG GAG GAA GTG GAT CCG CGG CCG CCA TTG AGG GCC GCC 3' (Seq. Id. No. 18) and 5' TCG AGG CGG CCC TCA ATG GCG GCC GCG GAT CCA CTT CCT CCT CCT CCA CTT CCT CCT CCT CCA CTT CCT CCT CCT CCT CCT 3' (Seq. Id. No. 19).

A second pair of complementary oligonucleotides were synthesized and annealed to form a DNA duplex encoding a trimerization domain derived from the isoleucine variant of the yeast GCN4 leucine zipper molecule. The duplex contained NotI compatible overhangs on both ends. The oligonucleotides were designed such that the 5' NotI site was destroyed but the 3' site remained intact. The sequences of the oligonucleotides were as follows: 5' GGCC ATG AAA CAA ATT GAA GAC AAG ATT GAA GAA ATT CTA TCA AAA ATT TAT CAC ATT GAA AAC GAA ATT GCC AGA ATT AAA AAA CTA ATT GGC GAA GC 3' (Seq. Id. No. 20) and 5' GGCCGC TTC GCC AAT TAG TTT TTT AAT TCT GGC AAT TTC GTT TTC AAT GTG ATA AAT TTT TGA TAG AAT TTC TTC AAT CTT GTC TTC AAT TTG TTT CAT 3' (Seq. Id. No. 21). The duplex was ligated into the NotI site of pCIneosCARNot to generate the plasmid pGStriCARa. Next, pGStriCARa was digested with both NotI and XhoI, the ends were blunted using Mung Bean Nuclease and ligated to generate the plasmid pGStriCARb, which encodes sCAR followed by a glycine/serine linker, the isoleucine variant GCN4 trimerization domain, and a 6 His Tag.

Plasmids encoding trimerized versions of sCAR containing an apoE targeting ligand domain were constructed as follows. First a pair of complementary oligonucleotides were synthesized and annealed to form a DNA duplex encoding the apoE targeting ligand

domain consisting of two tandem copies of amino acids 141 to 155 derived from apolipoproteinE. The duplex contained a NotI site near the 5' end and a XhoI site near the 3' end. The sequences of the oligonucleotides were as follows: 5' GCGGCC GCG CTG CGC AAG CTG CGT AAG CGG CTC CTC CGC GAT GCC GAT GAC CTG CTG CGC AAG CTG CGT AAG CGG CTC CTC CGC GAT GCC GAT GAC CTG CTC GAG CAC CAT 3' (Seq. Id. No. 22) and 5' ATG GTG CTC GAG CAG GTC ATC GGC ATC GCG GAG GAG CCG CTT ACG CAG CTT GCG CAG CAG GTC ATC GGC ATC GCG GAG GAG CCG CTT ACG CAG CTT GCG CAG CGC GGC CGC 3' (Seq. Id. No. 23). The duplex was digested with both NotI and XhoI and ligated into pGStriCARa which had been digested with both NotI and XhoI, to generate pGStriCARaapoE. Next, a linker element was inserted upstream of the targeting ligand domain as follows. A pair of complementary oligonucleotides were synthesized and annealed to generate a DNA duplex encoding a serine/alanine linker with NotI sites near each end. The sequences of the oligonucleotides were as follows: 5' GGCC CCA TCA GCC TCC GCA TCT GCT TCC GCC CCT GGA TCC GC 3' (Seq. Id. No. 24) and 5' GGCC GC GGA TCC AGG GGC GGA AGC AGA TGC GGA GGC TGA TGG GGC CGC 3' (Seq. Id. No. 25). The duplex was digested with NotI and ligated into the NotI site of pGStriCARaapoE to generate pGStriCARapoE.

Example 3: Production and purification of sCAR conjugated to a targeting ligand domain

To generate sCAR protein conjugated to a targeting ligand domain, an expression plasmid encoding the fusion protein, either pCI-neo-sCAR-cRGD, pCI-neo-sCAR-apoE, pGStriCARb, or pGStriCARapoE was introduced into COS-7 cells by electroporation. Prior to electroporation the cells were resuspended in RPMI, 20% fetal bovine serum (FBS), HEPES at a final concentration of 1×10^7 cells per milliliter. An aliquot of 500 µl of

cells was placed into a 4 mm electroporation cuvette and 25 µg of plasmid DNA was added to the cells. Electroporation was performed using a BTX instrument with settings R3, 2100 µF, and 264 volts.

At various times after electroporation, the medium was removed from the cells and replaced with fresh medium. The medium was dialyzed against PBS to remove glutamine and any other components which may interfere with His-tag binding to the Ni-NTA resin (Qiagen). Ni-NTA resin was added to the medium and mixed for 2 hours at 4° C. The resin with bound protein was pelleted by centrifugation and washed several times with 50 mM NaH_2PO_4, 0.5 M NaCl, 60 mM imidazole, pH 8.0. Fusion proteins were eluted from the resin with 50 mM NaH_2PO_4, 0.5 M NaCl, 400 mM imidazole, pH 8.0. Removal of imidazole, buffer exchange, and concentration of purified proteins was performed using Centricon Plus-20 concentrators (Millipore). The purified proteins were stored at -70°C in 1X PBS, 10% glycerol.

Example 4: Production and purification of trimerized sCAR fused to an apoE targeting ligand domain

To generate trimerized sCAR protein fused with an apoE targeting ligand domain, an expression plasmid encoding the fusion protein, pGStriCARapoE, was introduced into COS-7 cells by electroporation. The day after electroporation, the medium was removed from the cells and replaced with fresh medium. The next day, the cells were washed with PBS then lysed by adding 2 ml of RIPA buffer (5 mM Tris pH 8.0, 0.15 M NaCl, 1% deoxycholate, 1% NP-400) plus 1 mM PMSF (phenylmethylsulfonylfluoride). The cells were sheared by passing through a 21 guage needle. The cell lysate was incubated on ice for 30 minutes. The lysate was centrifuged at 10,000 rpm for 20 minutes to remove cell debris. The supernatant was transferred to a clean tube and Ni-NTA resin was added (150 µl per 10 cm plate). The tube was rocked at 4º C for 1 hour. The resin with bound

sCAR fusion protein was collected by centrifugation at 3500 rpm for 5 minutes. The supernatant was removed and the resin was transferred to a clean tube and washed twice with 800 µl of Wash buffer (50 mM $NaPO_4$, 500 mM NaCl, 40 mM imidazole, 10% glycerol). The resin was washed a third time with Wash buffer containing 60 mM imidazole and a fourth time with Wash buffer containing 80 mM imidazole. The sCAR fusion protein was eluted from the resin using 100 – 400 µl Elution buffer (50 mM $NaPO_4$, 500 mM NaCl, 400 mM imidazole, 10% glycerol).

Example 5: Western analysis of sCAR

The expression plasmid pCIneosCAR, that encodes the extracellular domain of CAR with a His-Tag at the carboxy-terminus, was electroporated into COS-7 cells. Prior to electroporation the cells were resuspended at a concentration of 1 x 10^7 cells per millimeter in RPMI medium containing 20% fetal bovine serum (FBS) and 10 mM HEPES (pH 7.4). An aliquot of 500 µl of cells was placed into a 4 mm electroporation cuvette and 25 µg of plasmid DNA was added to the cells. Electroporation was performed using a BTX instrument with settings R3, 2100 µF, and 264 volts. Media samples were collected on days 1, 2, 3, 4, and 7 after electroporation and the presence of sCAR was demonstrated by Western analysis using an anti-His-Tag antibody. The results showed that sCAR protein was continuously secreted from COS-7 cells for at least seven days. The identity of the protein was confirmed by a second Western analysis using purified IgG from rabbit antisera against sCAR as the probe.

Example 6: Generation of ^{35}S-labeled Ad5 fiber and cell binding assay

The ability of sCAR to bind adenovirus fiber protein was assessed by examining its ability to block binding of radioactively labeled fiber to cells. Ad5 fiber protein was produced and radioactively labeled in vitro using the T7 coupled transcription/translation reticulocyte

lysate system (Promega). A 1 µg aliquot of plasmid DNA encoding fiber was incubated with the system components including 40 µCi of L-^{35}S-methionine in a total volume of 50 µl for 20 hours at 30°c. A 1 µl aliquot of the labeled protein mixture was analyzed by non-denaturing SDS- 4-15% PAGE and fluorography. The result showed significant levels of ^{35}S-labeled trimerized fiber protein. The ^{35}S-labeled fiber was mixed with various amounts of sCAR protein then applied to either HepG2 or HDF cell monolayers in a 6-well dish at a density of 1 x 10^6 cells per well. ^{35}S-labeled cell bound protein were analyzed by SDS-4-15% PAGE and fluorography. The results showed that fiber binding to cells was blocked by addition of increasing amounts of sCAR protein.

Example 7: Adenovirus-mediated target cell transduction

Typically, sCAR protein was incubated with 2 x 10^9 particles of Av3GFP, an E1, E2a, E3 deleted adenoviral vector containing an RSV promoted green fluorescent protein (GFP) cDNA. , for 30 minutes at room temperature in a total volume of 50 µl in PBS. Following incubation, the complex was diluted to 1 ml with the appropriate tissue culture medium plus 2% FBS, then added to 6-well plates containing 1 x 10^6 cells, either human diploid fibroblasts (HDFs) or HepG2 cells. Cells were washed with 1X PBS prior to the addition of sCAR-adenoviral vector complex. Cells were incubated with the complex for 2 hours at 37°C then the medium was changed and the cells were incubated at 37°C another 24 to 48 hours. Cells were observed for green fluorescence under a Nikon fluorescence microscope. In some cases, to demonstrate specificity of binding, the cells were pre-blocked with either 10 µg per ml of competing Ad5 fiber protein or antibody against human LDL receptor or excess cRGD peptide for 30 minutes at 37°C before addition of the sCAR-adenoviral vector complex. The results showed that trimerized sCAR protein, without a targeting ligand domain, efficiently blocked transduction of HepG2 cells. Monomeric sCAR protein also blocked transduction of HepG2 cells, although much greater amounts of monomeric sCAR protein were required to achieve the same degree

of blocking.

Example 8: Complex formation and purification

A complex of Av3GFP vector with sCARcRGD protein was formed with a 550 times molar excess of sCAR to fiber monomer. Purified vector, 4 x 10^{11} particles of Av3GFP in 200 µl, was mixed with 115 µl of partially purified sCARcRGD protein (400 µg) at room temperature for 30 minutes. The reaction mixture was then centrifuged in 1.33 g/ml CsCl at 60,000 rpm overnight in a Beckman Vti65.2 rotor. The virus-complex band was isolated and dialyzed into buffer containing 10% glycerol, 200 mM Tris, 50 mM HEPES adjusted to pH 8.0 with phosphoric acid. Particle concentration was determined by measuring absorbance at 260 nm.

Example 9: Targeting Adenovirus to human diploid fibroblasts with sCAR-cRGD

The ability of sCAR conjugated to a targeting ligand domain to alter vector tropism was evaluated. First, pCIneo-CAR-cRGD, was transfected into COS-7 cells by electroporation. Media was collected two, four, and six days after electroporation and sCAR-cRGD protein was isolated and partially purified by binding to Ni-NTA resin. The protein was mixed with an adenoviral vector encoding green fluorescent protein, Av3GFP, and the complex was aded to a monolayer of human diploid fibroblasts (HDFs). Normally, HDFs are poorly transduced by adenovirus because the cells express little or no CAR on their surface. When unmodified Av3GFP was added to HDFs at a high multiplicity of infection (MOI), less than 1% of the cells expressed GFP. However, when sCAR-cRGD was added to Av3GFP, transduction of HDFs was efficient because the cells express the integrins recognized by cRGD.

Example 10: Targeting Adenovirus to HepG2 cells with sCAR-ApoE

The receptors recognized by the apoE ligand are expressed at high levels on the surface of hepatocytes, including HepG2 cells which were derived from a hepatocellular carcinoma. Unmodified Av3GFP transduced HepG2 cells with high efficiency because hepatocytes express CAR on their surface. However, transduction was blocked in the presence of high levels of purified adenovirus fiber protein due to competition between purified fiber with fiber on the vector capsid for binding to CAR on the cell surface. Transduction of HepG2 cells with Av3GFP complexed with sCAR-apoE was not blocked by purified fiber protein, indicating that vector was bound to cells via the apoE ligand.

Further evidence that the apoE ligand was mediating the interaction with the cell via an LDL receptor was provided by competition experiments using an antibody against LDL receptor. Transduction of HepG2 cells by Av3GFP complexed with sCAR-apoE was blocked by anti-human LDL receptor antibody. In contrast, the antibody did not have any effect on transduction by unmodified Av3GFP.

Example 11: Stability of soluble CAR adenovirus complex

To evaluate the stability of sCAR bound to an Av3GFP adenoviral vector, the ability to withstand centrifugation banding in cesium chloride followed by freezing, thawing and incubation in human serum for 60 minutes at room temperature was measured. A complex of Av3GFP with sCAR-cRGD was generated and CsCl banded as described in Example 8. The activity of CsCl banded complex was compared to the activity of freshly formed complex which was prepared by mixing 4 x 10^9 particles of Av3GFP with 17.5 µg of sCAR-cRGD protein (2400 times molar excess of sCAR to fiber monomer) in a 50 µl reaction mixture in PBS for 30 minutes at room temperature.

Human diploid fibroblasts (HDF) were cultured in 6-well dishes at 5 x 10^5 cells per well.

Cells were transduced at 37 ºC in 2% FBS in DMEM media with 4 x 10^9 particles per well of CsCl-banded complex. Control cells were transduced with 4 x 10^9 particles per well of purified Av3GFP vector alone or freshly formed Av3GFP/sCARcRGD complex. Infection media was removed after two hours and replaced with 10% FBS in DMEM. Cells were monitored for GFP expression 24 hours later.

CsCl-banded Av3GFP/sCARcRGD complex was frozen in dialysis buffer and stored at -80 ºC. HDF cells were cultured in 6-well dishes at 1 x 10^6 cells per well. Thawed complex, 4 x 10^9 particles in 11 µl, was mixed with 89 µl of PBS and immediately put onto cells or incubated for 60 minutes in PBS at room temperature. Similarly, 4 x 10^9 particles of thawed complex, 11 µl, was mixed with 89 µl normal mouse serum and incubated at room temperature for 30 minutes or 60 minutes. HDF cells were transduced with 4 x 10^9 particles per well of thawed CsCl-banded complex with or without pre-incubation in normal mouse serum. Control cells were transduced with 4 x 10^9 particles per well of purified Av3GFP vector alone or freshly formed Av3GFP/sCARcRGD complex for 2 hours at 37 ºC in 2% FBS in DMEM media. Infection media was removed and replaced with 10% FBS in DMEM. Cells were monitored for GFP expression 24 hours later.

As shown in Figure 2, unmodified Av3GFP did not transduce HDFs efficiently. This was expected because HDFs do not express CAR on their surface. However, Av3GFP complexed with sCARcRGD did transduce the cells efficiently. Additionally, the results showed that the Av3GFP/sCARcRGD complex was stable through CsCl banding, freezing and thawing, and exposure to serum.

Example 12: Trimerization of sCAR significantly enhances its function

^{35}S-labeled Ad5 fiber protein was mixed with purified sCAR protein and subjected to electrophoresis on a non-denaturing acrylamide gel. Autoradiography of the dried gel

demonstrated that ^{35}S-fiber was bound primarily to the trimeric form of sCAR. Bands were not visible at positions corresponding to monomeric or dimeric forms of sCAR. However, coomassie staining of non-denaturing gels showed that the large majority of sCAR was in a monomeric form. These observations suggested that trimers of sCAR had a significantly higher affinity for fiber than either monomers or dimers, but also suggested that trimers of sCAR were rare.

To increase the abundance of trimers of sCAR, a sequence encoding the GCN4 trimerization domain was inserted into the sCAR expression plasmid at the 3' end of the sequence encoding the extracellular domain of CAR. To increase the likelihood that the trimerization domains would be accessible to one another to promote the formation of sCAR trimers, a linker consisting of alternating glycine and serine residues was inserted between the end of sCAR and the trimerization domain. The resulting expression plasmid was introduced into COS cells by electroporation and sCAR protein was isolated and purified as described above.

The ability of sCAR containing a trimerization domain to block transduction of HepG2 cells by the adenoviral vector Av3GFP was compared to that of sCAR without a trimerization domain. HepG2 cells were seeded into 6 well dishes at a density of 5×10^5 cells per well. The next day, Av3GFP was treated with various amounts of both types of sCAR, either containing or lacking the trimerization domain. HepG2 cells were transduced with either untreated Av3GFP, Av3GFP treated with sCAR without a trimerization domain, or Av3GFP treated with sCAR containing a trimerization domain. Cells were transduced at an MOI of 3500 vector particles per cell. Cells were harvested 24 hours after transduction and GFP expression was measured by FACS analysis.

The results (Table 1) showed a significantly enhanced ability of trimerized sCAR to block transduction of HepG2 cells by Av3GFP. Experiment A shows the result for mock

transduced cells, which was used to establish the division between GFP positive and negative cells. Cells transduced with unmodified Av3GFP were 98% positive (Experiment B). The extent to which sCAR without a trimerization domain was able to block transduction of cells is shown in Experiments C and D; 10 µg of sCAR reduced transduction to 79% positive cells and 20 µg of sCAR reduced transduction to 69% positive cells. The enhanced ability of trimerized sCAR to block transduction is demonstrated in Experiments E-G, where a significant shift of the peaks toward untransduced cells is observed.

Table 1:

Experiment	% GFP Positive
A Mock transduced	0
B Av3GFP	98
C Av3GFP + 10 µg monomeric sCAR	79
D Av3GFP + 20 µg monomeric sCAR	69
E Av3GFP + 5 µg trimeric sCAR	43
F Av3GFP + 10 µg trimeric sCAR	32
G Av3GFP + 20 µg trimeric sCAR	32

Table 1. HepG2 cells were transduced with Av3GFP at an MOI of 3500 particles per cell. Twenty-four hours after transduction the cells were harvested and analyzed by FACS for GFP expression. (A) Mock transduced cells. (B) Cells transduced with Av3GFP alone. (C) Cells transduced with Av3GFP in the presence of 10 µg of monomeric sCAR. (D) Cells transduced with Av3GFP in the presence of 20 µg of monomeric sCAR. (E) Cells transduced with Av3GFP in the presence of 5 µg of trimeric sCAR. (F) Cells transduced with Av3GFP in the presence of 10 µg of trimeric sCAR. (G) Cells transduced with Av3GFP in the presence of 20 µg of trimeric sCAR.

In addition, trimerized versions of sCAR containing a targeting ligand domain demonstrated an enhanced ability to transduce human diploid fibroblasts (HDFs) compared to monomeric versions of sCAR containing the same targeting ligand domain. The adenoviral vector Av3GFP was mixed with various amounts of either trimerized sCAR containing an apoE ligand or monomeric sCAR containing the apoE ligand. The adenoviral vector and sCAR fusion protein were allowed to associate for 30 minutes at 37º C before adding the complex to HDFs, which had been seeded into the wells of a 6 well dish the prior day at a density of 5×10^5 cells per well. In each case, an MOI of 5000 vector particles per cell was used. The day after transduction, the cells were harvested and analyzed by fluorescence activated cell sorting (FACS) for GFP expression. The results are shown in Figure 3. HDFs express little or no CAR on their surface and therefore are poorly transduced by unmodified adenoviral vector. Av3GFP without the addition of a sCAR fusion protein yielded 8.3 % GFP positive cells. As shown in Figure 3, sCAR fused with an apoE targeting ligand domain yielded efficient transduction of HDFs. Notably, much lower amounts of the trimerized version of sCAR apoE were required to permit transduction of HDFs compared to the monomeric version. These results support the finding that trimerization of sCAR significantly enhances its function.

Example 13: Altered tropism of an adenoviral vector in vivo using sCAR

This example demonstrates the utility of sCAR for targeting an adenoviral vector in vivo. The need for targeting is exemplified by the widespread tissue distribution of vector following peripheral vein administration. Preclinical studies in rodents, dogs, and non-human primates have demonstrated that an adenoviral vector transduces most organs and tissues examined following systemic administration. In mice, the highest level of transduction is seen in the liver, however, most other tissues show significant levels of vector. This example shows that trimerized sCAR without a targeting ligand domain can efficiently block

transduction of the liver. In contrast, the monomeric form of sCAR does not effectively block liver transduction.

Av3nBg, an adenoviral vector encoding ß-galactosidase, was administered to C57BL/6 male mice via tail vein injection at a dose of 5×10^{10} particles per mouse. Cohorts of five mice received either unmodified adenoviral vector or vector complexed with either monomeric or trimeric sCAR. In cases where sCAR was added to the vector prior to injection, either 3 µg or 15 µg of sCAR protein was mixed with the adenoviral vector for 30 minutes at room temperature.

Three days after vector delivery, the animals were sacrificed and tissues, including liver, lung, heart, kidney, and spleen were collected. Slices of each tissue approximately 2-3 mm thick were placed in 10% neutral buffered formalin. After fixation, these samples were embedded in paraffin, sectioned, and analyzed by immunohistochemistry for ß-galactosidase expression. Other pieces of tissue were placed in eppendorf tubes and frozen on dry ice. These tissue samples were used to isolate DNA for Southern analyses to determine the vector content and also to analyze β-galactosidase expression using a chemiluminescent assay (Tropix, Inc.). Standard procedures were used to isolate DNA from the tissues. Briefly, tissue is minced and digested overnight at 37° C in 1% sodium dodecyl sulfate (SDS) and proteinase K (250 µg/ml). This is followed by phenol-chloroform extraction, Rnase treatment, a second phenol-chloroform extraction, chloroform-isoamyl alcohol extraction, ethanol precipitation, and resuspension in water. Ten micrograms of each DNA sample wasdigested with HindIII and subjected to Southern analysis. The probe was a radioactively labeled DNA fragment of the β-galactosidase cDNA.

The results showed expression of β-galactosidase in the liver following delivery of unmodified Av3nBg. In addition, Southern analysis showed that the liver contained

significant levels of vector. Av3nBg that was mixed with monomeric sCAR prior to injection yielded the same levels of β-galactosidase expression in the liver and the same vector content in the liver as unmodified vector. However, Av3nBg complexed with trimerized sCAR showed significantly reduced β-galactosidase expression in the liver and reduced levels of vector in the liver, demonstrating that trimerized sCAR effectively blocks transduction.

Expression of ß-galactosidase in the liver was assessed by immunohistochemical staining of tissue sections. In mice that received unmodified Av3nBg, approximately 10 – 15% of hepatocytes expressed ß-galactosidase. Monomeric sCAR, had no effect on the percentage of hepatocytes expressing transgene;. In contrast, trimeric sCAR effectively blocked liver transduction so that less than 1% of hepatocytes were positive for ß-galactosidase expression.

A second assay for β-galactosidase expression confirmed the results of immunohistochemical staining. The Galato-Light Plus β-galactosidase reporter gene assay system (Tropix, Inc.) was used to measure β-galactosidase expression in liver samples. The results are shown in Figure 4. Group 1 mice did not receive any adenoviral vector. Group 2 mice received Av3nBg alone. Group 3 mice received Av3nBg complexed with 3 μg of sCAR trimer. Group 4 mice received Av3nBg complexed with 15 μg of sCAR trimer. Group 5 mice received Av3nBg complexed with 3 μg of sCAR monomer. Group 6 mice received Av3nBg complexed with 15 μg of sCAR monomer. The results showed that sCAR trimer effectively blocked liver transduction by the adenoviral vector. However, the monomeric version of sCAR did not block liver transduction efficiently. These results support the conclusion that trimerization of sCAR is required to achieve effective function.

Example 14: Human CAR sequence

Seq. Id. No. 1: Human CAR DNA sequence (CDS = 60 - 1157):

gaattcccag gagcgagagc cgcctacctg cagccgccgc ccacggcacg gcagccacca tggcgctcct gctgtgcttc gtgctcctgt gcggagtagt ggatttcgcc agaagtttga gtatcactac tcctgaagag atgattgaaa aagccaaagg ggaaactgcc tatctgccgt gcaaatttac gcttagtccc gaagaccagg gaccgctgga catcgagtgg ctgatatcac cagctgataa tcagaaggtg gatcaagtga ttattttata ttctggagac aaaatttatg atgactacta tccagatctg aaaggccgag tacattttac gagtaatgat ctcaaatctg gtgatgcatc aataaatgta acgaatttac aactgtcaga tattggcaca tatcagtgca aagtgaaaaa agctcctggt gttgcaaata agaagattca tctggtagtt cttgttaagc cttcaggtgc gagatgttac gttgatggat ctgaagaaat tggaagtgac tttaagataa aatgtgaacc aaaagaaggt tcacttccat tacagtatga gtggcaaaaa ttgtctgact cacagaaaat gcccacttca tggttagcag aaatgacttc atctgttata tctgtaaaaa atgcctcttc tgagtactct gggacataca gctgtacagt cagaaacaga gtgggctctg atcagtgcct gttgcgtcta aacgttgtcc ctccttcaaa taaagctgga ctaattgcag gagccattat aggaactttg cttgctctag cgctcattgg tcttatcatc ttttgctgtc gtaaaaagcg cagagaagaa aaatatgaaa aggaagttca tcacgatatc agggaagatg tgccacctcc aaagagccgt acgtccactg ccagaagcta catcggcagt aatcattcat ccctggggtc catgtctcct tccaacatgg aaggatattc caagactcag tataaccaag taccaagtga agactttgaa cgcactcctc agagtccgac tctcccacct gctaaggtag ctgcccctaa tctaagtcga atgggtgcga ttcctgtgat gattccagca cagagcaagg atgggtctat agtatagagc ctccatatgt ctcatctgtg ctctccgtgt tcctttcctt tttttgatat atgaaaacct attctggtct aaattgtgtt actagcctca aaatacatca aaaaataagt taatcaggaa ctgtacggaa tatattttta aaaatttttg tttggttata tcgaaatagt tacaggcact aaagttagta aagaaaagtt taccatctga aaaagctgga ttttctttaa gaggttgatt ataaagtttt ctaaatttat cagtacctaa gtaagatgta gcgctttgaa tatgaaatca taggtgaaga catgggtgaa cttacttgca taccaagttg atacttgaat aaccatctga aagtggtact tgatcatttt taccattatt tttaggatgt gtatttcatt tatttatggc ccaccagtct cccccaaatt agtacagaaa tatccatgac aaaattactt acgtatgttt gtacttggtt ttacagctcc tttgaaaact ctgtgtttgg aatatctcta aaaacataga aaacactaca gtggtttaga aattactaat tttacttcta agtcattcat aaaccttgtc tatgaaatga cttcttaaat atttagttga tagactgcta caggtaatag ggacttagca agctctttta tatgctaaag gagcatctat cagattaagt tagaacattt gctgtcagcc acatattgag atgacactag gtgcaatagc agggatagat tttgttggtg agtagtctca tgccttgaga tctgtggtgg tcttcaaaat ggtggccagc cagatcaagg atgtagtatc tcatagttcc caggtgatat ttttcttatt agaaaaatat tataactcat ttgttgtttg acacttatag attgaaattt cctaatttat tctaaatttt aagtggttct ttggttccag tgctttatgt tgttgttgtt

tttggatggt gttacatatt atatgttcta gaaacatgta atcctaaatt taccctcttg aatataatcc ctggatgata ttttttatca taaatgcaga ataatcaaat acattttaag caagttaagt gtcctccatc aattctgtat tccagacttg ggaggatgta cagttgctgt tgtgtgatca aacatgtctc tgtgtagttc cagcaaatca agctgagctt tgaaaaagtt tgtcttagtt ttgtgaaggt gatttattct tagaaaaaaa aaaaaaaaaa aaaa

Seq. Id. No. 2: Human CAR amino acid sequence:

MALLLCFVLLCGVVDFARSLSITTPEEMIEKAKGETAYLPCKFT
LSPEDQGPLDIEWLISPADNQKVDQVIILYSGDKIYDDYYPDLKGRVHFTSNDLKSGD
ASINVTNLQLSDIGTYQCKVKKAPGVANKKIHLVVLVKPSGARCYVDGSEEIGSDFKI
KCEPKEGSLPLQYEWQKLSDSQKMPTSWLAEMTSSVISVKNASSEYSGTYSCTVRNRV
GSDQCLLRLNVVPPSNKAGLIAGAIIGTLLALALIGLIIFCCRKKRREEKYEKEVHHD
IREDVPPPKSRTSTARSYIGSNHSSLGSMSPSNMEGYSKTQYNQVPSEDFERTPQSPT
LPPAKVAAPNLSRMGAIPVMIPAQSKDGSIV

Example 15: Efficacy of the oncolytic adenovirus Ar6pAOscE3F complexed with sCARt-cRGD: In vivo analysis of trimeric sCAR targeting molecules in tumor bearing mice

Methods:

Adenoviral Vector. Ar6pAOscE3F is an oncolytic adenoviral vector containing the osteocalcin promoter to drive E1 expression and subsequent viral replication. A preparation of this vector was prepared using standard Cesium Chloride gradient purification methods.

Production of the trimeric sCAR targeting molecule. To generate the trimeric sCARt-cRGD targeting molecule used in these studies, the sCARt-cRGD expression plasmid was introduced into COS-7 cells by electroporation. The proteins were purified from cell lysates utilizing Ni-NTA resin (Qiagen) as described previously in Examples 3 and 4.

Cells. The human prostatic adenocarcinoma line PC3 (ATCC# CRL-1455) was obtained from American Type Culture Collection (Manassas, VA). The PC3 cells were cultured in RPMI 1640 media containing 10% Fetal Bovine Serum.

Subcutaneous tumor xenograft model in nude mice. Female athymic outbred nu/nu mice (Harlen Sprague Dawley), 6 to 7 weeks of age, were implanted with $3x10^6$ PC3 cells subcutaneously in the right flank. Matrigel (Collaborative Biomedical Products) was added to the cells at a 1:1 ratio to enhance tumor formation. Tumor measurements were recorded (in two dimensions) twice-weekly using microcallipers. Tumor volumes were calculated using the formula Length x $Width^2$ x $\pi/6$. A study cohort of animals with tumor volumes of 90-200 mm^3 were selected and evenly distributed into groups (n=15 per group, mean tumor volumes of 110mm^3) and injected intravenously with the virus alone or complexed with the trimeric sCAR targeting molecule as described in Table 2. A negative control group received the same volume of HBSS. The trimeric sCAR targeting molecule was mixed at a 1:10 molar ratio and allow to interact for 30 minutes at room temperature prior to injection.

Table 2. Study design for the in vivo analysis of the trimeric sCARt-cRGD targeting molecule

Group	Mice (n)	Test Article	Dose (particles/kg)
1	20	HBSS	---
2	20	Ar6pAOscE3F	1 x 1013
3	20	Ar6pAOscE3F + sCARt-cRGD	1 x 1013

On study days 1, 3, and 7 blood was collected from five animals per group for evaluation of

liver toxicity. Tumor measurements were carried out twice per week for the duration of the study.

Blood was collected by retro-orbital sinus bleeds from 5 mice per group on study days 1, 3, and 7. Serum was collected and submitted to AniLytics, Inc. (Gaithersburg, MD) for clinical chemistry analyses. Parameters analyzed were alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Increased serum levels of both ALT and AST are indicative of hepatocellular injury.

Results:

PC3 cells formed tumors of 90-200 mm3 approximately ten days after subcutaneous injection into nude mice. A single intraveneous injection of virus alone or complexed with the trimeric sCAR targeting molecule at a dose of 1×10^{13} particles per kilogram was administered. At this viral dose there was no morbidity.

Blood samples were harvested from the mice on study days 1, 3, 7 and serum levels of ALT and AST were measured (Figure 7). HBSS and Ar6pAOscE3F/sCARt-cRGD groups showed low levels of enzymes at all three time points. However the group treated with Ar6pAOscE3F showed elevated serum levels of ALT and AST compared to the other groups. Thus, adenoviral-mediated liver toxicity is reduced when oncolytic adenoviruses are systemcially delivered using the trimeric sCARt-cRGD targeting molecule. This is a result of less virus being allowed to transduced the liver as has previously been shown in Examples 12 and 13.

The ultimate goal of this study was to demonstrate systemic delivery of oncolytic adenoviruses using trimeric sCARt targeting molecules to tumors leads to improved efficacy. To address this goal, the Ar6pAOscE3F oncolytic adenoviral vector was delivered intravenously alone or complexed with the sCARt-cRGD targeting molecule. Tumor volumes

were determined twice per week for the duration of the study. Figure 8 shows the average tumor volume over time for each treatment group. The average tumor volume for the HBSS and virus alone groups increased over time from a starting tumor volume of approximately 120 mm^3 up to average tumor volumes of 359.8 and 335.4 mm^3 at study day 18, respectively. When the Ar6pAOscE3F oncolytic adenovirus was delivered systemically using the sCARt-cRGD targeting molecule, the tumors did not increase in size as rapidly and resulted in a significantly lower tumor volume at study 18 (p=0.028).

In summary, these in vivo results demonstrate the adenoviral vectors can be delivered systemically to specific sites using trimeric sCAR targeting molecules. Delivery of oncolytic adenoviral vectors using the sCAR-tcRGD targeting molecule resulted in decreased liver transduction as shown by reduced liver toxicity and improved efficacy as shown by reduced tumor volumes.

The disclosures of all patents, publications (including published patent applications), and database accession numbers referred to in this specification are specifically incorporated herein by reference in their entirety to the same extent as if each such individual patent, publication and database number were specifically and individually indicated to be incorporated by reference in its entirety.

WHAT IS CLAIMED IS:

1. A targeting molecule comprising a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain.

2. The targeting molecule according to claim 1 wherein the soluble adenoviral receptor domain is sCAR.

3. The targeting molecule according to claim 1 wherein the trimerization domain is derived from a leucine zipper molecule.

4. The targeting molecule according to claim 1 wherein the trimerization domain is the isoleucine variant of the yeast GCN4 leucine zipper molecule.

5. The targeting molecule according to claim 1 wherein the trimerization domain is fused with the soluble adenoviral receptor domain.

6. The targeting molecule according to claim 5 wherein the trimerization domain is fused at the carboxy-terminal end of the soluble adenoviral receptor domain.

7. The targeting molecule according to claim 1 further comprising a linker element which is localized between the carboxy-terminal end of the soluble adenoviral receptor domain and the trimerization domain.

8. The targeting molecule according to claim 7 wherein the linker element consists of alternating glycine and serine residues.

9. The targeting molecule according to claim 1 wherein the targeting ligand domain is cyclic RGD.

10. The targeting molecule according to claim 1 wherein the targeting ligand domain includes at least 15 amino acids derived from an apoE protein.

11. The targeting molecule according to claim 10 wherein the targeting ligand domain includes two tandem copies of amino acids 141-155 derived from apoE protein.

12. The targeting molecule according to claim 1 wherein the targeting ligand domain is conjugated to the carboxy-terminus of the soluble adenoviral receptor domain.

13. The targeting molecule according to claim 1 further comprising a linker element which is localized between the carboxy-terminal end of the trimerization domain and the targeting ligand domain.

14. The targeting molecule according to claim 1 wherein the soluble adenoviral receptor domain is sCAR and the trimerization domain is derived from a leucine zipper molecule.

15. A trimeric targeting molecule comprising the targeting molecule according to claim 1.

16. A complex comprising an adenoviral particle and the targeting molecule according to claim 1.

17. The complex according to claim 16 wherein the soluble adenoviral receptor domain is sCAR.

18. The complex according to claim 16 wherein the trimerization domain is derived from a leucine zipper molecule.

19. The complex according to claim 16 further comprising a linker element which is localized between the carboxy-terminal end of the soluble adenoviral receptor domain and the trimerization domain.

20. The complex according to claim 16 wherein the soluble adenoviral receptor domain is sCAR and the trimerization domain is derived from a leucine zipper molecule.

21. The complex according to claim 16 wherein the adenoviral particle further comprises a heterologous gene.

22. The complex according to claim 16 wherein the adenoviral particle is an oncolytic adenoviral particle.

23. A polynucleotide encoding the targeting molecule according to claim 1.

24. An expression vector comprising a polynucleotide according to claim 23.

25. A method of targeting an adenoviral particle to a cell which expresses a cell surface molecule comprising the steps of (a) contacting an adenoviral particle with the targeting molecule of claim 1 to form a complex comprising said adenoviral particle and said targeting molecule and (b) contacting said cell with said complex.

26. The method of claim 25 wherein the adenoviral particle is an oncolytic adenoviral particle.

27. A method of delivering a heterologous gene selectively to a cell which expresses a cell surface molecule comprising the steps of (a) contacting an adenoviral particle which comprises said heterologous gene with the targeting molecule of claim 1 to form a complex suitable to target said cell surface molecule and (b) contacting said cell with said complex.

28. A method for identifying, either or both, a cell surface molecule that is suitable for mediating cell entry of an adenoviral particle to a specific cell or tissue expressing said cell surface molecule, or a ligand that is suitable for targeting an adenoviral particle to a specific cell or tissue, comprising the steps of, 1) combining a ligand molecule for a cell surface molecule with a soluble adenoviral receptor molecule and a trimerization domain to form a targeting molecule, 2) contacting an adenoviral particle which comprises a marker gene with the targeting molecule to form a complex, 3) contacting a cell or tissue expressing said cell surface molecule with said complex, and 4) selecting a complex able to transduce efficiently said cell or tissue as reported by the marker gene.

29. The targeting molecule according to claim 1, wherein the targeting ligand domain comprises a single chain antibody (scFv).

30. The complex of any of claims 16 to 22 for use as a medicament.

31. Use of the complex of any of claims 16 to 22 for the preparation of a medicament for the treatment of a disease in a mammal including a human.

32. The use of claim 31 wherein the disease is cancer.

33. The use of claim 32 wherein the cancer is an adenocarcinoma of the prostate.

34. A method for the treatment of a disease with adenoviral gene therapy comprising contacting a trimeric targeting molecule of claim 15 with an adenoviral gene therapy vector to form a complex, and administering said complex in a therapeutically effective amount to a patient in need thereof.

35. The method of claim 34 wherein the disease is cancer.

36. The method of claim 35 wherein the cancer is an adenocarcinoma of the prostate.

37. The method of claim 34 wherein the side effects of the gene therapy are reduced.

38. The method of claim 37 wherein the side effect of adenoviral liver toxicity is reduced.

Figure 1


14
238 258
365
Human CAR
LS
EXTRACELLULAR DOMAIN
TM
ID
14
238
sCAR-cRGD
LS
EXTRACELLULAR DOMAIN
Linker cRGD His-tag
14
238
sCAR-ApoE
LS
EXTRACELLULAR DOMAIN
Linker ApoE His-tag
sCAR-trimer
LS
EXTRACELLULAR DOMAIN
Linker TriD His-tag
sCAR-trimer-apoE
LS
EXTRACELLULAR DOMAIN
Linker TriD ApoE His-tag

Figure 2


Av3GFP
Av3GFP + sCARcRGD
Av3GFP + sCARcRGD
CsCl banded and Freeze/thawed
Av3GFP + sCARcRGD
CsCl banded and Freeze/thawed
60 minutes in serum

Figure 3


Av3GFP Transduction of HDFs
% GFP Positive Cells
100
80
60
40
20
0
0.001
0.01
0.1
1
10
sCAR (ug)
sCAR trimer apoE
sCAR monomer apoE

Figure 4

Liver b-Gal Assay
Light Units/ug Protein (Average per Group)



Figure 5


BglII
MunI
NruI
MluI
SspI
NdeI
SnaBI
ScaI
PvuI
NheI
AflII
HindIII
Asp718I
KpnI
BamHI
EcoRI
EcoRV
NotI
XhoI
XbaI
EcoO109I
ApaI
Bsp120I
cmv PR
AMP
5000
AhdI
1000
bgh pA
BbsI
PCDNA3~1.SEQ
5432 bps
4000
ColE1
DraIII
2000
3000
SexAI
BspLU11I
BseRI
StuI
AvrII
SmaI
XmaI
BsaBI
Bst1107I
BsmI
NspV
RsrII
BbeI
EheI
KasI
NarI
BalI
Tth111I
BssHII

Figure 6


PCINEO
5474 bps
CMV IE
CMV Pro
Intron
T7
T3
SV40 PA
F1
Sv40EP
Neo
PA
Ampr
1000
2000
3000
4000
5000
BglII
BsrGI
SpeI
NdeI
SnaBI
SgfI
Ecl136II
SacI
BbsI
HpaI
MunI
DraIII
SexAI
SfiI
BseRI
StuI
AvrII
BbeI
EheI
KasI
NarI
Tth111I
BssHII
RsrII
NspV
BstXI
BamHI
EcoO109I
XmnI
AhdI
GsuI
AlwNI
NheI
XhoI
EcoRI
AflIII
MluI
XbaI
AccI
SalI
SmaI
XmaI
NotI

Figure 7


A. AST
Serum AST (Units/ml)
6000
5000
4000
3000
2000
1000
0
24 hrs
72 hrs
1 week
Time Post Injection
B. ALT
HBSS
OV 1x10¹³vp/kg
OV + sCARt-cRGD
Serum ALT (Units/ml)
3000
2500
2000
1500
1000
500
0
24 hrs
72 hrs
1 week
Time Post Injection

Figure 8


HBSS
OV 1x10[13] vp/kg
OV + sCARt-cRGD 1x10[13] vp/kg
Tumor Volume (mm³) mean ± SEM, n=15
450
400
350
300
250
200
150
100
50
0
0
2
4
6
8
10
12
14
16
18
20
Study Day
*

sCAR2.ST25.txt

SEQUENCE LISTING

<110> Novartis AG

<120> Targeting molecules

<130> 4-31615/GTI

<160> 25

<170> PatentIn version 3.0

<210> 1

<211> 2434

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (60)..(1157)

<400> 1

```
gaattcccag gagcgagagc cgcctacctg cagccgccgc ccacggcacg gcagccacc      59

atg gcg ctc ctg ctg tgc ttc gtg ctc ctg tgc gga gta gtg gat ttc      107
Met Ala Leu Leu Leu Cys Phe Val Leu Leu Cys Gly Val Val Asp Phe
1               5                  10                  15

gcc aga agt ttg agt atc act act cct gaa gag atg att gaa aaa gcc      155
Ala Arg Ser Leu Ser Ile Thr Thr Pro Glu Glu Met Ile Glu Lys Ala
            20                  25                  30

aaa ggg gaa act gcc tat ctg ccg tgc aaa ttt acg ctt agt ccc gaa      203
Lys Gly Glu Thr Ala Tyr Leu Pro Cys Lys Phe Thr Leu Ser Pro Glu
        35                  40                  45

gac cag gga ccg ctg gac atc gag tgg ctg ata tca cca gct gat aat      251
Asp Gln Gly Pro Leu Asp Ile Glu Trp Leu Ile Ser Pro Ala Asp Asn
    50                  55                  60

cag aag gtg gat caa gtg att att tta tat tct gga gac aaa att tat      299
Gln Lys Val Asp Gln Val Ile Ile Leu Tyr Ser Gly Asp Lys Ile Tyr
```

```
65                  70                  75                  80

gat gac tac tat cca gat ctg aaa ggc cga gta cat ttt acg agt aat      347
Asp Asp Tyr Tyr Pro Asp Leu Lys Gly Arg Val His Phe Thr Ser Asn
                85                  90                  95

gat ctc aaa tct ggt gat gca tca ata aat gta acg aat tta caa ctg      395
Asp Leu Lys Ser Gly Asp Ala Ser Ile Asn Val Thr Asn Leu Gln Leu
            100                 105                 110

tca gat att ggc aca tat cag tgc aaa gtg aaa aaa gct cct ggt gtt      443
Ser Asp Ile Gly Thr Tyr Gln Cys Lys Val Lys Lys Ala Pro Gly Val
        115                 120                 125

gca aat aag aag att cat ctg gta gtt ctt gtt aag cct tca ggt gcg      491
Ala Asn Lys Lys Ile His Leu Val Val Leu Val Lys Pro Ser Gly Ala
    130                 135                 140

aga tgt tac gtt gat gga tct gaa gaa att gga agt gac ttt aag ata      539
Arg Cys Tyr Val Asp Gly Ser Glu Glu Ile Gly Ser Asp Phe Lys Ile
145                 150                 155                 160

aaa tgt gaa cca aaa gaa ggt tca ctt cca tta cag tat gag tgg caa      587
Lys Cys Glu Pro Lys Glu Gly Ser Leu Pro Leu Gln Tyr Glu Trp Gln
                165                 170                 175

aaa ttg tct gac tca cag aaa atg ccc act tca tgg tta gca gaa atg      635
Lys Leu Ser Asp Ser Gln Lys Met Pro Thr Ser Trp Leu Ala Glu Met
            180                 185                 190

act tca tct gtt ata tct gta aaa aat gcc tct tct gag tac tct ggg      683
Thr Ser Ser Val Ile Ser Val Lys Asn Ala Ser Ser Glu Tyr Ser Gly
        195                 200                 205

aca tac agc tgt aca gtc aga aac aga gtg ggc tct gat cag tgc ctg      731
Thr Tyr Ser Cys Thr Val Arg Asn Arg Val Gly Ser Asp Gln Cys Leu
    210                 215                 220

ttg cgt cta aac gtt gtc cct cct tca aat aaa gct gga cta att gca      779
Leu Arg Leu Asn Val Val Pro Pro Ser Asn Lys Ala Gly Leu Ile Ala
225                 230                 235                 240

gga gcc att ata gga act ttg ctt gct cta gcg ctc att ggt ctt atc      827
Gly Ala Ile Ile Gly Thr Leu Leu Ala Leu Ala Leu Ile Gly Leu Ile
                245                 250                 255

atc ttt tgc tgt cgt aaa aag cgc aga gaa gaa aaa tat gaa aag gaa      875
Ile Phe Cys Cys Arg Lys Lys Arg Arg Glu Glu Lys Tyr Glu Lys Glu
            260                 265                 270

gtt cat cac gat atc agg gaa gat gtg cca cct cca aag agc cgt acg      923
Val His His Asp Ile Arg Glu Asp Val Pro Pro Pro Lys Ser Arg Thr
        275                 280                 285

tcc act gcc aga agc tac atc ggc agt aat cat tca tcc ctg ggg tcc      971
Ser Thr Ala Arg Ser Tyr Ile Gly Ser Asn His Ser Ser Leu Gly Ser
    290                 295                 300

atg tct cct tcc aac atg gaa gga tat tcc aag act cag tat aac caa     1019
Met Ser Pro Ser Asn Met Glu Gly Tyr Ser Lys Thr Gln Tyr Asn Gln
305                 310                 315                 320

gta cca agt gaa gac ttt gaa cgc act cct cag agt ccg act ctc cca     1067
```

Val Pro Ser Glu Asp Phe Glu Arg Thr Pro Gln Ser Pro Thr Leu Pro
325 330 335

cct gct aag gta gct gcc cct aat cta agt cga atg ggt gcg att cct 1115
Pro Ala Lys Val Ala Ala Pro Asn Leu Ser Arg Met Gly Ala Ile Pro
340 345 350

gtg atg att cca gca cag agc aag gat ggg tct ata gta tag 1157
Val Met Ile Pro Ala Gln Ser Lys Asp Gly Ser Ile Val
355 360 365

agcctccata tgtctcatct gtgctctccg tgttcctttc ctttttttga tatatgaaaa 1217

cctattctgg tctaaattgt gttactagcc tcaaaataca tcaaaaaata agttaatcag 1277

gaactgtacg gaatatattt ttaaaaattt ttgtttggtt atatcgaaat agttacaggc 1337

actaaagtta gtaaagaaaa gtttaccatc tgaaaaagct ggattttctt taagaggttg 1397

attataaagt tttctaaatt tatcagtacc taagtaagat gtagcgcttt gaatatgaaa 1457

tcataggtga agacatgggt gaacttactt gcataccaag ttgatacttg aataaccatc 1517

tgaaagtggt acttgatcat ttttaccatt atttttagga tgtgtatttc atttatttat 1577

ggcccaccag tctcccccaa attagtacag aaatatccat gacaaaatta cttacgtatg 1637

tttgtacttg gttttacagc tcctttgaaa actctgtgtt tggaatatct ctaaaaacat 1697

agaaaacact acagtggttt agaaattact aattttactt ctaagtcatt cataaacctt 1757

gtctatgaaa tgacttctta aatatttagt tgatagactg ctacaggtaa tagggactta 1817

gcaagctctt ttatatgcta aaggagcatc tatcagatta agttagaaca tttgctgtca 1877

gccacatatt gagatgacac taggtgcaat agcagggata gattttgttg gtgagtagtc 1937

tcatgccttg agatctgtgg tggtcttcaa aatggtggcc agccagatca aggatgtagt 1997

atctcatagt tcccaggtga tatttttctt attagaaaaa tattataact catttgttgt 2057

ttgacactta tagattgaaa tttcctaatt tattctaaat tttaagtggt tctttggttc 2117

cagtgcttta tgttgttgtt gtttttggat ggtgttacat attatatgtt ctagaaacat 2177

gtaatcctaa atttaccctc ttgaatataa tccctggatg atatttttta tcataaatgc 2237

agaataatca aatacatttt aagcaagtta agtgtcctcc atcaattctg tattccagac 2297

ttgggaggat gtacagttgc tgttgtgtga tcaaacatgt ctctgtgtag ttccagcaaa 2357

tcaagctgag ctttgaaaaa gtttgtctta gttttgtgaa ggtgatttat tcttagaaaa 2417

aaaaaaaaaa aaaaaaa 2434

<210> 2

<211> 365

<212> PRT

<213> Homo sapiens

<400> 2

```
Met Ala Leu Leu Leu Cys Phe Val Leu Leu Cys Gly Val Val Asp Phe
1               5                  10                  15

Ala Arg Ser Leu Ser Ile Thr Thr Pro Glu Glu Met Ile Glu Lys Ala
            20                  25                  30

Lys Gly Glu Thr Ala Tyr Leu Pro Cys Lys Phe Thr Leu Ser Pro Glu
        35                  40                  45

Asp Gln Gly Pro Leu Asp Ile Glu Trp Leu Ile Ser Pro Ala Asp Asn
    50                  55                  60

Gln Lys Val Asp Gln Val Ile Ile Leu Tyr Ser Gly Asp Lys Ile Tyr
65                  70                  75                  80

Asp Asp Tyr Tyr Pro Asp Leu Lys Gly Arg Val His Phe Thr Ser Asn
                85                  90                  95

Asp Leu Lys Ser Gly Asp Ala Ser Ile Asn Val Thr Asn Leu Gln Leu
            100                 105                 110

Ser Asp Ile Gly Thr Tyr Gln Cys Lys Val Lys Lys Ala Pro Gly Val
        115                 120                 125

Ala Asn Lys Lys Ile His Leu Val Val Leu Val Lys Pro Ser Gly Ala
    130                 135                 140

Arg Cys Tyr Val Asp Gly Ser Glu Glu Ile Gly Ser Asp Phe Lys Ile
145                 150                 155                 160

Lys Cys Glu Pro Lys Glu Gly Ser Leu Pro Leu Gln Tyr Glu Trp Gln
                165                 170                 175

Lys Leu Ser Asp Ser Gln Lys Met Pro Thr Ser Trp Leu Ala Glu Met
            180                 185                 190

Thr Ser Ser Val Ile Ser Val Lys Asn Ala Ser Ser Glu Tyr Ser Gly
        195                 200                 205

Thr Tyr Ser Cys Thr Val Arg Asn Arg Val Gly Ser Asp Gln Cys Leu
    210                 215                 220

Leu Arg Leu Asn Val Val Pro Pro Ser Asn Lys Ala Gly Leu Ile Ala
225                 230                 235                 240
```

Gly Ala Ile Ile Gly Thr Leu Leu Ala Leu Ala Leu Ile Gly Leu Ile
245 250 255

Ile Phe Cys Cys Arg Lys Lys Arg Arg Glu Glu Lys Tyr Glu Lys Glu
260 265 270

Val His His Asp Ile Arg Glu Asp Val Pro Pro Pro Lys Ser Arg Thr
275 280 285

Ser Thr Ala Arg Ser Tyr Ile Gly Ser Asn His Ser Ser Leu Gly Ser
290 295 300

Met Ser Pro Ser Asn Met Glu Gly Tyr Ser Lys Thr Gln Tyr Asn Gln
305 310 315 320

Val Pro Ser Glu Asp Phe Glu Arg Thr Pro Gln Ser Pro Thr Leu Pro
325 330 335

Pro Ala Lys Val Ala Ala Pro Asn Leu Ser Arg Met Gly Ala Ile Pro
340 345 350

Val Met Ile Pro Ala Gln Ser Lys Asp Gly Ser Ile Val
355 360 365

<210> 3

<211> 93

<212> DNA

<213> Saccharomyces cerevisiae

<220>

<221> CDS

<222> (1)..(93)

<400> 3

atg aaa caa att gaa gac aag att gaa gaa att cta tca aaa att tat 48
Met Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr
1 5 10 15

cac att gaa aac gaa att gcc aga att aaa aaa cta att ggc gaa 93
His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu
20 25 30

<210> 4

<211> 31

<212> PRT

<213> Saccharomyces cerevisiae

<400> 4

Met Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr
1 5 10 15

His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu
20 25 30

<210> 5

<211> 9

<212> PRT

<213> Homo sapiens

<400> 5

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 6

<211> 90

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(90)

<400> 6
ctg cgc aag ctg cgt aag cgg ctc ctc cgc gat gcc gat gac ctg ctg 48
Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Leu
1 5 10 15

cgc aag ctg cgt aag cgg ctc ctc cgc gat gcc gat gac ctg 90
Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu
20 25 30

<210> 7

<211> 30

<212> PRT

<213> Homo sapiens

<400> 7

Leu Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Leu
1 5 10 15

Arg Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu
20 25 30

<210> 8

<211> 30

<212> DNA

<213> primer

<400> 8
gtaggatccg ccaccatggc gctcctgctg 30

<210> 9

<211> 30

<212> DNA

<213> primer

<400> 9
gcgcgaattc ctatactata gacccatcct 30

<210> 10

<211> 28

<212> DNA

<213> primer

<400> 10
actagctagc gccgccacca tggcgctc 28

<210> 11

<211> 56

<212> DNA

<213> primer

<400> 11
gtgatctaga ctagtgatga tggtgatggt gctcgagagc tttatttgaa ggaggg 56

<210> 12

<211> 63

<212> DNA

<213> primer

<400> 12
tcgaaccatc agcctccgca tctgcttccg cccctggatc cgcggccgcc attgagggcc 60

gcc 63

<210> 13

<211> 63

<212> DNA

<213> primer

<400> 13
tcgaggcggc cctcaatggc ggccgcggat ccaggggcgg aagcagatgc ggaggctgat 60

ggt 63

<210> 14

<211> 33

<212> DNA

<213> oligonucleotide

<400> 14
ggcctgcgat tgccgtggtg attgcttttg cgc 33

<210> 15

<211> 33

<212> DNA

<213> oligonucleotide

<400> 15
ggccgcgcaa aagcaatcac cacggcaatc gca 33

<210> 16

<211> 51

<212> DNA

<213> oligonucleotide

<400> 16
ggccctgcgc aagctgcgta agcggctcct ccgcgatgcc gatgacctgg c 51

<210> 17

<211> 51

<212> DNA

<213> oligonucleotide

<400> 17
ggccgccagg tcatcggcat cgcggaggag ccgcttacgc agcttgcgca g 51

<210> 18

<211> 78

<212> DNA

<213> oligonucleotide

<400> 18
tcgaaggagg aggaggaagt ggaggaggag gaagtggagg aggaggaagt ggatccgcgg 60

ccgccattga gggccgcc 78

<210> 19

<211> 78

<212> DNA

<213> oligonucleotide

<400> 19
tcgaggcggc cctcaatggc ggccgcggat ccacttcctc ctcctccact tcctcctcct 60

ccacttcctc ctcctcct 78

<210> 20

<211> 99

<212> DNA

<213> oligonucleotide

<400> 20
ggccatgaaa caaattgaag acaagattga agaaattcta tcaaaaattt atcacattga 60

aaacgaaatt gccagaatta aaaaactaat tggcgaagc 99

<210> 21

<211> 99

<212> DNA

<213> oligonucleotide

<400> 21
ggccgcttcg ccaattagtt ttttaattct ggcaatttcg ttttcaatgt gataaatttt 60

tgatagaatt tcttcaatct tgtcttcaat ttgtttcat 99

<210> 22

<211> 111

<212> DNA

<213> oligonucleotide

<400> 22
gcggccgcgc tgcgcaagct gcgtaagcgg ctcctccgcg atgccgatga cctgctgcgc 60

aagctgcgta agcggctcct ccgcgatgcc gatgacctgc tcgagcacca t 111

<210> 23

<211> 111

<212> DNA

<213> oligonucleotide

<400> 23
atggtgctcg agcaggtcat cggcatcgcg gaggagccgc ttacgcagct tgcgcagcag 60

gtcatcggca tcgcggagga gccgcttacg cagcttgcgc agcgcggccg c 111

<210> 24

<211> 42

<212> DNA

<213> oligonucleotide

<400> 24
ggccccatca gcctccgcat ctgcttccgc ccctggatcc gc 42

<210> 25

<211> 48

<212> DNA

<213> oligonucleotide

<400> 25
ggccgcggat ccaggggcgg aagcagatgc ggaggctgat ggggccgc 48

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/029072 A3

(51) International Patent Classification[7]: C12N 15/12, 15/62, 15/86, 15/47, C07K 14/705, A61K 48/00, G01N 33/50

(21) International Application Number: PCT/EP01/11514

(22) International Filing Date: 5 October 2001 (05.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/684,552 6 October 2000 (06.10.2000) US
60/327,562 6 October 2000 (06.10.2000) US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA AG** [AT/AT]; Brunner Strasse 59, 1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIM, Jin, Gwan** [US/US]; 11520 Seneca Forest Circle, Germantown, MD 20876 (US). **SMITH, Theodore** [US/US]; 3346 Knolls Parkway, Ijamsville, MD 21754 (US). **STEVENSON, Susan, C.** [US/US]; 10974 Horseshoe Drive, Frederick, MD 21701 (US). **KALEKO, Michael** [US/US]; 8 Hearthstone Court, Rockville, MD 20854 (US).

(74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
9 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/029072 A3

(54) Title: TARGETTING MOLECULES FOR ADENOVIRAL VECTORS

(57) Abstract: The present invention relates to targeting molecules which are useful to specifically target an adenoviral particle to a desired cell type. These targeting molecules comprise a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain. Further provided are polynucleotides encoding such targeting molecule, expression vectors including such polynucleotides, and methods to target an adenoviral particle to a cell, as well as methods to deliver a heterologous gene selectively to a cell.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/11514

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C12N15/62 C12N15/86 C12N15/87 C07K14/705
A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
BIOSIS, EPO-Internal, MEDLINE, EMBASE, SCISEARCH, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DMITRIEV IGOR ET AL: "Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells." JOURNAL OF VIROLOGY, vol. 74, no. 15, August 2000 (2000-08), pages 6875-6884, XP002227911 ISSN: 0022-538X the whole document --- -/--	

[X] Further documents are listed in the continuation of box C.

[ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 January 2003	04/02/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Niemann, F

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
T	KASHENTSEVA ELENA A ET AL: "Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain." CANCER RESEARCH, vol. 62, no. 2, 15 January 2002 (2002-01-15), pages 609-616, XP002227912 January 15, 2002 ISSN: 0008-5472 the whole document	
T	KIM JIN ET AL: "Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: Improved potency via trimerization." JOURNAL OF VIROLOGY, vol. 76, no. 4, February 2002 (2002-02), pages 1892-1903, XP002227913 February, 2002 ISSN: 0022-538X the whole document	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/11514

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 25-27 (in so far as it relates to in vivo methods), 34-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.